\r\n\tAnother area of uncertainty is the potential effect following the suspension/ interruption of some chronic therapies in defined clinical situations.
\r\n
\r\n\t \r\n\tThe purpose of this text is to highlight both the positive and negative aspects of polytherapy in elderly subjects and when it should be necessary to take into consideration the regulated suspension (deprescribing) of one or more drugs. In particular, it would be important reducing or avoiding the prevalence of negative effects, which can even accelerate cognitive or physical decay, leading sometimes to premature death.
",isbn:null,printIsbn:"979-953-307-X-X",pdfIsbn:null,doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"2f7692d7459d00b0ab41e5f7bb0fd57a",bookSignature:"Dr. Oreste Capelli and Dr. Maria Isabella Bonacini",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/9611.jpg",keywords:"Drug Efficacy, Cardiovascular Drugs, Preventive Therapy, Drug Safety, Chronic Conditions, Drugs Interactions, Prescribing Cascade, Deprescribing Algorithm, Holistic Care, Proton Pump Inhibitors, Palliative Care, Limited Life Expectancy",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"June 15th 2020",dateEndSecondStepPublish:"July 6th 2020",dateEndThirdStepPublish:"September 4th 2020",dateEndFourthStepPublish:"November 23rd 2020",dateEndFifthStepPublish:"January 22nd 2021",remainingDaysToSecondStep:"8 months",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:null,kuFlag:!1,biosketch:"Dr. Capelli was the referent for the care pathways for chronic diseases of the Emilia Romagna Region and from 2015 to 2019 he was Director of the Clinical Governance and Medical Library of the Local Health Authority of Modena. Dr. Capelli was a member of the local Research Ethics Committee, he has held hundreds of seminars on the topics of EBHC, Clinical Governance, and Prescriptive Appropriateness.",coeditorOneBiosketch:"She is a senior pharmacist and she specializes in hepatology – virus hepatitis and liver transplant. She is an independent prescriber and has an academic post-graduate diploma with Bath University in Pharmaceutical Practice & Therapeutics. She is currently working at Plymouth University Hospitals NHS Trust where she runs her own viral clinic. She has interests in developing the educational and teaching program within both the pharmacy department and the nurse's preceptorship (with UHP).",coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"110047",title:"Dr.",name:"Oreste",middleName:null,surname:"Capelli",slug:"oreste-capelli",fullName:"Oreste Capelli",profilePictureURL:"https://mts.intechopen.com/storage/users/110047/images/system/110047.jpg",biography:"Dr. Oreste Capelli graduated in Medicine and Surgery with honors in 1981, specialized in 1985 in Pneumology and in 1992 in Internal Medicine. In 2003 he obtained a master's degree in Evidence-Based Medicine and Research Methodology, in 2010 a three-year degree in Systemic Counseling and in 2015 the master's degree in Direction and Management of Health Services.\nHe worked as Hospital Pulmonologist from 1985 to 1990, then as a General Practitioner until 2003. From 2004 to 2019 he held various positions in Public Health, as a Clinical Methodologist and Researcher in the Organization of care pathways for Chronic Diseases. From 2012 to 2014 he was the referent for the care pathways for chronic diseases of the Emilia Romagna Region and from 2015 to 2019 he was Director of the Clinical Governance and Medical Library of the Local Health Authority of Modena.\nFrom 2017 to 2019 he was a member of the local Research Ethics Committee.\nDr. Capelli has held hundreds of seminars on the topics of EBHC, Clinical Governance, and Prescriptive Appropriateness. He is a co-author of numerous scientific articles, book chapters, and speeches at national and international conferences.",institutionString:"Local Health Authority of Modena",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"7",totalChapterViews:"0",totalEditedBooks:"2",institution:null}],coeditorOne:{id:"317210",title:"Dr.",name:"Maria Isabella",middleName:null,surname:"Bonacini",slug:"maria-isabella-bonacini",fullName:"Maria Isabella Bonacini",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00002sukYhQAI/Profile_Picture_1577101764343",biography:"Maria Isabella Bonacini graduated in Chemistry and Pharmaceutical Technology in 2001.\nShe undertaken and successfully completed the Postgraduate General Level Programme in Pharmaceutical Practice & Therapeutics, University of Bath (September 2013) and the Pharmaceutical Technology Quality Assurance (PTQA), University of Manchester (September 2015).\n\nIn August 2019 she became a non-medical independent prescriber (UWE, Bristol).\n\n She has been working within NHS (Hospital) in the UK since November 2008 as a clinical pharmacist. She developed her role as a pharmacist within the Technical Service department and for a number of years she managed the operation of the Quality Control Laboratory in accordance with GMP (by following the departmental environmental monitoring procedures including room pressures and use of microbiological monitoring). She has clinical experience in nutrition support (dealing with Consultant GI and Dietitician in prescribing TPN within Nutrition Clinic).\n\nShe’s currently appointed as Hepatology Pharmacist at Derriford Hospital (NHS Trust), Plymouth.",institutionString:"University Hospitals Plymouth NHS Trust",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"University Hospitals Plymouth NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"247865",firstName:"Jasna",lastName:"Bozic",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/247865/images/7225_n.jpg",email:"jasna.b@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"1886",title:"Primary Care at a Glance",subtitle:"Hot Topics and New Insights",isOpenForSubmission:!1,hash:"aa9970e335b085064f8b2b9cc44fb81d",slug:"primary-care-at-a-glance-hot-topics-and-new-insights",bookSignature:"Oreste Capelli",coverURL:"https://cdn.intechopen.com/books/images_new/1886.jpg",editedByType:"Edited by",editors:[{id:"110047",title:"Dr.",name:"Oreste",surname:"Capelli",slug:"oreste-capelli",fullName:"Oreste Capelli"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4650",title:"Primary Care in Practice",subtitle:"Integration is Needed",isOpenForSubmission:!1,hash:"3e8540a822eeae65ea19979f52abb25b",slug:"primary-care-in-practice-integration-is-needed",bookSignature:"Oreste Capelli",coverURL:"https://cdn.intechopen.com/books/images_new/4650.jpg",editedByType:"Edited by",editors:[{id:"110047",title:"Dr.",name:"Oreste",surname:"Capelli",slug:"oreste-capelli",fullName:"Oreste Capelli"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"26692",title:"Respiratory Care for Myasthenic Crisis",doi:"10.5772/30174",slug:"respiratory-care-for-myasthenic-crisis",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/26692.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/26692",previewPdfUrl:"/chapter/pdf-preview/26692",totalDownloads:15289,totalViews:214,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,dateSubmitted:"March 15th 2011",dateReviewed:"August 17th 2011",datePrePublished:null,datePublished:"January 20th 2012",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/26692",risUrl:"/chapter/ris/26692",book:{slug:"a-look-into-myasthenia-gravis"},signatures:"Ping-Hung Kuo and Pi-Chuan Fan",authors:[{id:"81171",title:"Dr.",name:"Ping-Hung",middleName:null,surname:"Kuo",fullName:"Ping-Hung Kuo",slug:"ping-hung-kuo",email:"kph712@ntuh.gov.tw",position:null,institution:{name:"National Taiwan University Hospital",institutionURL:null,country:{name:"Taiwan"}}},{id:"123082",title:"Dr.",name:"Pi-Chuan",middleName:null,surname:"Fan",fullName:"Pi-Chuan Fan",slug:"pi-chuan-fan",email:"pcf712@gmail.com",position:null,institution:null}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"735",title:"A Look into Myasthenia Gravis",subtitle:null,fullTitle:"A Look into Myasthenia Gravis",slug:"a-look-into-myasthenia-gravis",publishedDate:"January 20th 2012",bookSignature:"Joseph A. Pruitt",coverURL:"https://cdn.intechopen.com/books/images_new/735.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"78215",title:"Dr.",name:"Joseph A.",middleName:null,surname:"Pruitt",slug:"joseph-a.-pruitt",fullName:"Joseph A. Pruitt"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"26688",title:"Myasthenia Gravis with Anti-MuSK Antibodies: Clinical Features and Histopathological Changes",slug:"myasthenia-gravis-with-anti-musk-antibodies-clinical-features-and-histopathological-changes",totalDownloads:6413,totalCrossrefCites:1,signatures:"Corrado Angelini, Sara Martignago, Michela Biscigli and Elisa Albertini",authors:[{id:"90338",title:"Prof.",name:"Corrado",middleName:null,surname:"Angelini",fullName:"Corrado Angelini",slug:"corrado-angelini"},{id:"90817",title:"Dr.",name:"Sara",middleName:null,surname:"Martignago",fullName:"Sara Martignago",slug:"sara-martignago"},{id:"90818",title:"Dr.",name:"Michela",middleName:null,surname:"Bisciglia",fullName:"Michela Bisciglia",slug:"michela-bisciglia"},{id:"90820",title:"Dr.",name:"Elisa",middleName:null,surname:"Albertini",fullName:"Elisa Albertini",slug:"elisa-albertini"}]},{id:"26689",title:"Ocular Manifestations of Myasthenia Gravis",slug:"ocular-manifestations-of-myasthenia-gravis",totalDownloads:2465,totalCrossrefCites:0,signatures:"Joseph A. Pruitt and Pauline Ilsen",authors:[{id:"78215",title:"Dr.",name:"Joseph A.",middleName:null,surname:"Pruitt",fullName:"Joseph A. Pruitt",slug:"joseph-a.-pruitt"},{id:"124474",title:"Dr.",name:"Pauline",middleName:null,surname:"Ilsen",fullName:"Pauline Ilsen",slug:"pauline-ilsen"}]},{id:"26690",title:"Myasthenia Gravis – Current Treatment Standards and Emerging Drugs",slug:"myasthenia-gravis-current-treatment-standards-and-emerging-drugs",totalDownloads:5825,totalCrossrefCites:1,signatures:"Kamil Musilek, Marketa Komloova, Ondrej Holas, Anna Horova, Jana Zdarova-Karasova and Kamil Kuca",authors:[{id:"27865",title:"MSc.",name:"Ondrej",middleName:null,surname:"Holas",fullName:"Ondrej Holas",slug:"ondrej-holas"},{id:"27866",title:"Ms.",name:"Anna",middleName:null,surname:"Horova",fullName:"Anna Horova",slug:"anna-horova"},{id:"27868",title:"Dr.",name:"Jana",middleName:null,surname:"Zdarova-Karasova",fullName:"Jana Zdarova-Karasova",slug:"jana-zdarova-karasova"},{id:"27870",title:"Prof.",name:"Kamil",middleName:null,surname:"Kuca",fullName:"Kamil Kuca",slug:"kamil-kuca"},{id:"85705",title:"Dr.",name:"Kamil",middleName:null,surname:"Musilek",fullName:"Kamil Musilek",slug:"kamil-musilek"},{id:"85707",title:"MSc.",name:"Marketa",middleName:null,surname:"Komloova",fullName:"Marketa Komloova",slug:"marketa-komloova"}]},{id:"26691",title:"Immunomodulatory Treatments for Myasthenia Gravis: Plasma Exchange, Intravenous Immunoglobulins and Semiselective Immunoadsorption",slug:"immunomodulatory-treatments-for-myasthenia-gravis-plasmaexchange-intravenous-immunoglobulins-and-sem",totalDownloads:3498,totalCrossrefCites:0,signatures:"Fulvio Baggi and Carlo Antozzi",authors:[{id:"89921",title:"Dr.",name:"Fulvio",middleName:null,surname:"Baggi",fullName:"Fulvio Baggi",slug:"fulvio-baggi"},{id:"94738",title:"Dr.",name:"Carlo",middleName:null,surname:"Antozzi",fullName:"Carlo Antozzi",slug:"carlo-antozzi"}]},{id:"26692",title:"Respiratory Care for Myasthenic Crisis",slug:"respiratory-care-for-myasthenic-crisis",totalDownloads:15289,totalCrossrefCites:0,signatures:"Ping-Hung Kuo and Pi-Chuan Fan",authors:[{id:"81171",title:"Dr.",name:"Ping-Hung",middleName:null,surname:"Kuo",fullName:"Ping-Hung Kuo",slug:"ping-hung-kuo"},{id:"123082",title:"Dr.",name:"Pi-Chuan",middleName:null,surname:"Fan",fullName:"Pi-Chuan Fan",slug:"pi-chuan-fan"}]},{id:"26693",title:"Unilaterally Extended Thoracoscopic Thymectomy: The Right Side or the Left Side Approach",slug:"unilaterally-extended-thoracoscopic-thymectomy-the-right-side-or-the-left-side-approach",totalDownloads:1608,totalCrossrefCites:0,signatures:"Victor Tomulescu",authors:[{id:"88449",title:"Dr.",name:"Victor",middleName:null,surname:"Tomulescu",fullName:"Victor Tomulescu",slug:"victor-tomulescu"}]},{id:"26694",title:"Robotic Thymectomy",slug:"robotic-thymectomy",totalDownloads:1593,totalCrossrefCites:0,signatures:"Victor Tomulescu",authors:[{id:"88449",title:"Dr.",name:"Victor",middleName:null,surname:"Tomulescu",fullName:"Victor Tomulescu",slug:"victor-tomulescu"}]}]},relatedBooks:[{type:"book",id:"1388",title:"Autoimmune Disorders",subtitle:"Current Concepts and Advances from Bedside to Mechanistic Insights",isOpenForSubmission:!1,hash:"f3365e915e5d7c7299da6c076aa5cf24",slug:"autoimmune-disorders-current-concepts-and-advances-from-bedside-to-mechanistic-insights",bookSignature:"Fang-Ping Huang",coverURL:"https://cdn.intechopen.com/books/images_new/1388.jpg",editedByType:"Edited by",editors:[{id:"42618",title:"Dr.",name:"Fang-Ping",surname:"Huang",slug:"fang-ping-huang",fullName:"Fang-Ping Huang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"20659",title:"Autoimmune Disorders Associated to Type 1 Diabetes Mellitus in Children and Adolescents",slug:"autoimmune-disorders-associated-to-type-1-diabetes-mellitus-in-children-and-adolescents",signatures:"Giuseppe d’Annunzio and Chiara Russo, Ramona Tallone and Renata Lorini",authors:[{id:"39758",title:"Dr.",name:"Giuseppe",middleName:null,surname:"D'Annunzio",fullName:"Giuseppe D'Annunzio",slug:"giuseppe-d'annunzio"},{id:"52571",title:"Dr.",name:"Chiara",middleName:null,surname:"Russo",fullName:"Chiara Russo",slug:"chiara-russo"},{id:"52572",title:"Prof.",name:"Renata",middleName:null,surname:"Lorini",fullName:"Renata Lorini",slug:"renata-lorini"},{id:"53744",title:"Dr.",name:"Ramona",middleName:null,surname:"Tallone",fullName:"Ramona Tallone",slug:"ramona-tallone"}]},{id:"20660",title:"Hashimoto's Thyroiditis in Children and Adolescents",slug:"hashimoto-s-thyroiditis-in-children-and-adolescents",signatures:"Erkan Sarı, Abdulbaki Karaoglu and Ediz Yeşilkaya",authors:[{id:"59265",title:"Dr.",name:"Ediz",middleName:null,surname:"Yesilkaya",fullName:"Ediz Yesilkaya",slug:"ediz-yesilkaya"},{id:"59267",title:"Dr.",name:"Erkan",middleName:null,surname:"Sari",fullName:"Erkan Sari",slug:"erkan-sari"},{id:"91048",title:"Dr.",name:"Abdulbaki",middleName:null,surname:"Karaoglu",fullName:"Abdulbaki Karaoglu",slug:"abdulbaki-karaoglu"}]},{id:"20661",title:"Primary Sjögren’s Syndrome: Current Pathophysiological, Diagnostic and Therapeutic Advances",slug:"primary-sjo-gren-s-syndrome-current-pathophysiological-diagnostic-and-therapeutic-advances",signatures:"Christine Delporte, Jason Perret and Muhammad S. Soyfoo",authors:[{id:"40743",title:"Prof.",name:"Christine",middleName:null,surname:"Delporte",fullName:"Christine Delporte",slug:"christine-delporte"},{id:"51555",title:"Prof.",name:"Jason",middleName:null,surname:"Perret",fullName:"Jason Perret",slug:"jason-perret"},{id:"51556",title:"Dr",name:"Muhammad",middleName:"Shahnawaz",surname:"Soyfoo",fullName:"Muhammad Soyfoo",slug:"muhammad-soyfoo"}]},{id:"20662",title:"Changing Spectrum of Chronic Immune Thrombocytopenic Purpura: New Face for an Old Disease",slug:"changing-spectrum-of-chronic-immune-thrombocytopenic-purpura-new-face-for-an-old-disease",signatures:"Indu Sabnani and Patricia Tsang",authors:[{id:"53121",title:"Dr.",name:"Indu",middleName:null,surname:"Sabnani",fullName:"Indu Sabnani",slug:"indu-sabnani"},{id:"53153",title:"Dr.",name:"Patricia",middleName:null,surname:"Tsang",fullName:"Patricia Tsang",slug:"patricia-tsang"}]},{id:"23462",title:"Autoimmune-Associated Hemophagocytic Syndrome/Macrophage Activation Syndrome",slug:"autoimmune-associated-hemophagocytic-syndrome-macrophage-activation-syndrome",signatures:"Maciej Machaczka, Wojciech Sydor, Małgorzata Rucińska, Marta Szostek and Jacek Musiał",authors:[{id:"37510",title:"Dr.",name:"Maciej",middleName:"J.",surname:"Machaczka",fullName:"Maciej Machaczka",slug:"maciej-machaczka"},{id:"53497",title:"Dr.",name:"Malgorzata",middleName:"Maria",surname:"Rucinska",fullName:"Malgorzata Rucinska",slug:"malgorzata-rucinska"},{id:"93873",title:"Dr.",name:"Wojciech",middleName:"J.",surname:"Sydor",fullName:"Wojciech Sydor",slug:"wojciech-sydor"},{id:"93874",title:"Dr.",name:"Marta",middleName:null,surname:"Szostek",fullName:"Marta Szostek",slug:"marta-szostek"},{id:"93875",title:"Prof.",name:"Jacek",middleName:null,surname:"Musial",fullName:"Jacek Musial",slug:"jacek-musial"}]},{id:"20664",title:"Ocular Myasthenia Analysis of Diagnostic and Treatment Options",slug:"ocular-myasthenia-analysis-of-diagnostic-and-treatment-options",signatures:"Austin Hake and Henry J. Kaminski",authors:[{id:"40795",title:"Dr.",name:"Henry",middleName:null,surname:"Kaminski",fullName:"Henry Kaminski",slug:"henry-kaminski"},{id:"136016",title:"Prof.",name:"Austin",middleName:null,surname:"Hake",fullName:"Austin Hake",slug:"austin-hake"}]},{id:"20665",title:"Sweet Syndrome",slug:"sweet-syndrome",signatures:"Manuel Ginarte and Jaime Toribio",authors:[{id:"35090",title:"Dr.",name:"Manuel",middleName:null,surname:"Ginarte",fullName:"Manuel Ginarte",slug:"manuel-ginarte"},{id:"136018",title:"Dr.",name:"Jaime",middleName:null,surname:"Toribio",fullName:"Jaime Toribio",slug:"jaime-toribio"}]},{id:"20666",title:"Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders",slug:"validation-of-protein-biomarkers-to-advance-the-management-of-autoimmune-disorders",signatures:"David S. Gibson, Sorcha Finnegan, Stephen Pennington, Ji Qiu, Joshua LaBaer, Madeleine E. Rooney and Mark W. Duncan",authors:[{id:"40972",title:"Dr.",name:"David",middleName:null,surname:"Gibson",fullName:"David Gibson",slug:"david-gibson"},{id:"40988",title:"Prof.",name:"Mark",middleName:null,surname:"Duncan",fullName:"Mark Duncan",slug:"mark-duncan"},{id:"89331",title:"Dr",name:"Sorcha",middleName:null,surname:"Finnegan",fullName:"Sorcha Finnegan",slug:"sorcha-finnegan"},{id:"89714",title:"Dr.",name:"Madeleine",middleName:null,surname:"Rooney",fullName:"Madeleine Rooney",slug:"madeleine-rooney"},{id:"89766",title:"Prof.",name:"Stephen",middleName:null,surname:"Pennington",fullName:"Stephen Pennington",slug:"stephen-pennington"},{id:"89767",title:"Dr.",name:"Ji",middleName:null,surname:"Qiu",fullName:"Ji Qiu",slug:"ji-qiu"},{id:"90269",title:"Prof.",name:"Joshua",middleName:null,surname:"LaBaer",fullName:"Joshua LaBaer",slug:"joshua-labaer"}]},{id:"20667",title:"Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases",slug:"relevance-of-autoantibodies-for-the-classification-and-pathogenesis-of-neurological-diseases",signatures:"Simone Mader, Benjamin Obholzer and Markus Reindl",authors:[{id:"39318",title:"Prof.",name:"Markus",middleName:null,surname:"Reindl",fullName:"Markus Reindl",slug:"markus-reindl"},{id:"39330",title:"Dr.",name:"Simone",middleName:null,surname:"Mader",fullName:"Simone Mader",slug:"simone-mader"},{id:"93770",title:"MSc.",name:"Benjamin",middleName:null,surname:"Obholzer",fullName:"Benjamin Obholzer",slug:"benjamin-obholzer"}]},{id:"20668",title:"Preclinical and Predictive Algorithms in Monitoring Patients with Autoimmune Diseases and Their Relatives-at-Risks",slug:"preclinical-and-predictive-algorithms-in-monitoring-patients-with-autoimmune-diseases-and-their-rela",signatures:"Sergey Suchkov, Dmitry Kostyushev, Dmitry Gnatenko, Sevindzh Gadzhieva and Mikhail Paltsev",authors:[{id:"40368",title:"Prof.",name:"Sergey",middleName:"Victorovich",surname:"Suchkov",fullName:"Sergey Suchkov",slug:"sergey-suchkov"},{id:"49152",title:"Dr.",name:"Dmitry",middleName:"Sergeevich",surname:"Kostyushev",fullName:"Dmitry Kostyushev",slug:"dmitry-kostyushev"},{id:"49153",title:"Prof.",name:"Dmitrii",middleName:null,surname:"Gnatenko",fullName:"Dmitrii Gnatenko",slug:"dmitrii-gnatenko"},{id:"49154",title:"Dr.",name:"Sevindj",middleName:null,surname:"Gadjieva",fullName:"Sevindj Gadjieva",slug:"sevindj-gadjieva"},{id:"49155",title:"Prof.",name:"Mihail",middleName:null,surname:"Paltsev",fullName:"Mihail Paltsev",slug:"mihail-paltsev"}]},{id:"20669",title:"Application of Novel Quantitative Proteomic Technologies to Identify New Serological Biomarkers in Autoimmune Diseases",slug:"application-of-novel-quantitative-proteomic-technologies-to-identify-new-serological-biomarkers-in-a",signatures:"Soyoung Lee, Satoshi Serada, Minoru Fujimoto and Tetsuji Naka",authors:[{id:"40263",title:"Prof.",name:"Tetsuji",middleName:null,surname:"Naka",fullName:"Tetsuji Naka",slug:"tetsuji-naka"},{id:"54042",title:"Prof.",name:"Satoshi",middleName:null,surname:"Serada",fullName:"Satoshi Serada",slug:"satoshi-serada"},{id:"54043",title:"Prof.",name:"Minoru",middleName:null,surname:"Fujimoto",fullName:"Minoru Fujimoto",slug:"minoru-fujimoto"},{id:"64673",title:"Dr.",name:"Soyoung",middleName:null,surname:"Lee",fullName:"Soyoung Lee",slug:"soyoung-lee"}]},{id:"20670",title:"Application of Monoclonal Antibody Therapies in Autoimmune Diseases",slug:"application-of-monoclonal-antibody-therapies-in-autoimmune-diseases",signatures:"Adrienn Angyal, Jozsef Prechl, Gyorgy Nagy and Gabriella Sarmay",authors:[{id:"54397",title:"Dr",name:"Adrienn",middleName:null,surname:"Angyal",fullName:"Adrienn Angyal",slug:"adrienn-angyal"},{id:"54406",title:"Prof.",name:"Jozsef",middleName:null,surname:"Prechl",fullName:"Jozsef Prechl",slug:"jozsef-prechl"},{id:"54407",title:"Prof.",name:"Gabriella",middleName:null,surname:"Sarmay",fullName:"Gabriella Sarmay",slug:"gabriella-sarmay"},{id:"145362",title:"Prof.",name:"György M.",middleName:null,surname:"Nagy",fullName:"György M. Nagy",slug:"gyorgy-m.-nagy"}]},{id:"20671",title:"The Emerging Role of Monoclonal Antibodies in the Treatmentof Systemic Lupus Erythematosus",slug:"the-emerging-role-of-monoclonal-antibodies-in-the-treatmentof-systemic-lupus-erythematosus",signatures:"Ewa Robak and Tadeusz Robak",authors:[{id:"34135",title:"Prof.",name:"Tadeusz",middleName:null,surname:"Robak",fullName:"Tadeusz Robak",slug:"tadeusz-robak"},{id:"34143",title:"Prof.",name:"Ewa",middleName:null,surname:"Robak",fullName:"Ewa Robak",slug:"ewa-robak"}]},{id:"20672",title:"Treatment of Pediatric-Onset Lupus Nephritis: A New Option of Less Cytotoxic Immunosuppressive Therapy",slug:"treatment-of-pediatric-onset-lupus-nephritis-a-new-option-of-less-cytotoxic-immunosuppressive-therap",signatures:"Hiroshi Tanaka and Tadaatsu Imaizumi",authors:[{id:"37530",title:"Dr.",name:"Hiroshi",middleName:null,surname:"Tanaka",fullName:"Hiroshi Tanaka",slug:"hiroshi-tanaka"},{id:"52589",title:"Dr.",name:"Tadaatsu",middleName:null,surname:"Imaizumi",fullName:"Tadaatsu Imaizumi",slug:"tadaatsu-imaizumi"}]},{id:"20673",title:"Recent Advances in the Treatment of Neurological Autoimmune Disorders",slug:"recent-advances-in-the-treatment-of-neurological-autoimmune-disorders",signatures:"Jagat R. Kanwar, Bhasker Sriramoju and Rupinder K. Kanwar",authors:[{id:"40068",title:"Prof.",name:"Jagat",middleName:"Rakesh",surname:"Kanwar",fullName:"Jagat Kanwar",slug:"jagat-kanwar"},{id:"53589",title:"Dr.",name:"Rupinder",middleName:null,surname:"Kanwar",fullName:"Rupinder Kanwar",slug:"rupinder-kanwar"}]},{id:"20674",title:"Synthetic Glucocorticoids Modulate Function of Neural Cells: Implications in Autoimmune Neurological Disorders",slug:"synthetic-glucocorticoids-modulate-function-of-neural-cells-implications-in-autoimmune-neurological-",signatures:"Oscar Gonzalez-Perez, Norma A. Moy-Lopez and Jorge Guzman-Muniz",authors:[{id:"35161",title:"Prof.",name:"Oscar",middleName:null,surname:"Gonzalez-Perez",fullName:"Oscar Gonzalez-Perez",slug:"oscar-gonzalez-perez"},{id:"94114",title:"Dr.",name:"Norma",middleName:null,surname:"Moy-Lopez",fullName:"Norma Moy-Lopez",slug:"norma-moy-lopez"},{id:"94115",title:"MSc.",name:"Jorge",middleName:null,surname:"Guzman-Muniz",fullName:"Jorge Guzman-Muniz",slug:"jorge-guzman-muniz"}]},{id:"20675",title:"Intravenous Immunoglobulins in Neurological Diseases: Established and Novel Clinical Applications",slug:"intravenous-immunoglobulins-in-neurological-diseases-established-and-novel-clinical-applications",signatures:"Konstantina G. Yiannopoulou",authors:[{id:"52626",title:"Dr.",name:"Konstantina",middleName:null,surname:"Yiannopoulou",fullName:"Konstantina Yiannopoulou",slug:"konstantina-yiannopoulou"}]},{id:"20676",title:"Cellular Based Therapies for the Treatment of Multiple Sclerosis",slug:"cellular-based-therapies-for-the-treatment-of-multiple-sclerosis",signatures:"James Crooks, Guang-Xian Zhang and Bruno Gran",authors:[{id:"38513",title:"Prof.",name:"Guang-Xian",middleName:null,surname:"Zhang",fullName:"Guang-Xian Zhang",slug:"guang-xian-zhang"},{id:"38803",title:"Dr.",name:"Bruno",middleName:null,surname:"Gran",fullName:"Bruno Gran",slug:"bruno-gran"},{id:"38804",title:"Mr.",name:"James",middleName:null,surname:"Crooks",fullName:"James Crooks",slug:"james-crooks"}]},{id:"20677",title:"Haematopoietic Cell Transplantation and Immunotherapy for Autoimmune Diseases in Children and Adults",slug:"haematopoietic-cell-transplantation-and-immunotherapy-for-autoimmune-diseases-in-children-and-adults",signatures:"Menachem Bitan",authors:[{id:"39092",title:"Dr.",name:"Menachem",middleName:null,surname:"Bitan",fullName:"Menachem Bitan",slug:"menachem-bitan"}]},{id:"20678",title:"Thionamides-Related Vasculitis in Autoimmune Thyroid Disorders: Review of Current Literature and Case Reports",slug:"thionamides-related-vasculitis-in-autoimmune-thyroid-disorders-review-of-current-literature-and-case",signatures:"Elisabetta L. Romeo, Giuseppina T. Russo, Annalisa Giandalia, Provvidenza Villari, Angela A. Mirto, Mariapaola Cucinotta, Giuseppa Perdichizzi and Domenico Cucinotta",authors:[{id:"53938",title:"Dr.",name:"Giuseppina T.",middleName:null,surname:"Russo",fullName:"Giuseppina T. Russo",slug:"giuseppina-t.-russo"},{id:"53940",title:"Dr.",name:"Elisabetta L.",middleName:null,surname:"Romeo",fullName:"Elisabetta L. Romeo",slug:"elisabetta-l.-romeo"},{id:"53941",title:"Dr.",name:"Annalisa",middleName:null,surname:"Giandalia",fullName:"Annalisa Giandalia",slug:"annalisa-giandalia"},{id:"95745",title:"Dr.",name:"Mariapaola",middleName:null,surname:"Cucinotta",fullName:"Mariapaola Cucinotta",slug:"mariapaola-cucinotta"},{id:"95746",title:"Prof.",name:"Giuseppa",middleName:null,surname:"Perdichizzi",fullName:"Giuseppa Perdichizzi",slug:"giuseppa-perdichizzi"},{id:"95749",title:"Prof.",name:"Domenico",middleName:null,surname:"Cucinotta",fullName:"Domenico Cucinotta",slug:"domenico-cucinotta"},{id:"115595",title:"Dr.",name:"Provvidenza",middleName:null,surname:"Villari",fullName:"Provvidenza Villari",slug:"provvidenza-villari"},{id:"115964",title:"Dr.",name:"Angela A.",middleName:null,surname:"Mirto",fullName:"Angela A. Mirto",slug:"angela-a.-mirto"}]},{id:"22843",title:"The Ectopic Germinal Centre Response in Autoimmune Disease and Cancer",slug:"the-ectopic-germinal-centre-response-in-autoimmune-disease-and-cancer",signatures:"David I. Stott and Donna McIntyre",authors:[{id:"110862",title:"Prof.",name:"David",middleName:"Ian",surname:"Stott",fullName:"David Stott",slug:"david-stott"},{id:"136021",title:"Dr.",name:"Donna",middleName:null,surname:"McIntyre",fullName:"Donna McIntyre",slug:"donna-mcintyre"}]},{id:"20680",title:"Myasthenia Gravis: New Insights into the Effect of MuSK Antibodies and Acetylcholinesterase Inhibitors",slug:"myasthenia-gravis-new-insights-into-the-effect-of-musk-antibodies-and-acetylcholinesterase-inhibitor",signatures:"Anna Rostedt Punga",authors:[{id:"38872",title:"Dr.",name:"Anna",middleName:"Rostedt",surname:"Punga",fullName:"Anna Punga",slug:"anna-punga"}]},{id:"20681",title:"Vasoactive Neuropeptides in Autoimmune Diseases",slug:"vasoactive-neuropeptides-in-autoimmune-diseases",signatures:"Ekua W. Brenu, Lotti Tajouri, Donald R. Staines and Sonya M. Marshall-Gradisnik",authors:[{id:"41142",title:"Ms",name:"Ekua",middleName:"Weba",surname:"Brenu",fullName:"Ekua Brenu",slug:"ekua-brenu"},{id:"53185",title:"Prof.",name:"Lotti",middleName:null,surname:"Tajouri",fullName:"Lotti Tajouri",slug:"lotti-tajouri"},{id:"53186",title:"Prof.",name:"Sonya",middleName:null,surname:"Marshall-Gradisnik",fullName:"Sonya Marshall-Gradisnik",slug:"sonya-marshall-gradisnik"},{id:"53187",title:"Prof.",name:"Don",middleName:null,surname:"Staines",fullName:"Don Staines",slug:"don-staines"}]},{id:"20682",title:"Antibody-Proteases in the Pathogenesis of Autoimmune Demyelination and Monitoring Patients with Multiple Sclerosis",slug:"antibody-proteases-in-the-pathogenesis-of-autoimmune-demyelination-and-monitoring-patients-with-mult",signatures:"Dmitry Kostyushev, Dmitry Gnatenko, Mikhail Paltsev, Aleksandr Gabibov and Sergey Suchkov",authors:[{id:"40368",title:"Prof.",name:"Sergey",middleName:"Victorovich",surname:"Suchkov",fullName:"Sergey Suchkov",slug:"sergey-suchkov"},{id:"49152",title:"Dr.",name:"Dmitry",middleName:"Sergeevich",surname:"Kostyushev",fullName:"Dmitry Kostyushev",slug:"dmitry-kostyushev"},{id:"49166",title:"Prof.",name:"Gabibov",middleName:null,surname:"Aleksandr",fullName:"Gabibov Aleksandr",slug:"gabibov-aleksandr"},{id:"107360",title:"Prof.",name:"Dmitrii",middleName:null,surname:"Gnatenko",fullName:"Dmitrii Gnatenko",slug:"dmitrii-gnatenko"},{id:"107467",title:"Prof.",name:"Mikhail",middleName:null,surname:"Paltsev",fullName:"Mikhail Paltsev",slug:"mikhail-paltsev"}]},{id:"20683",title:"Role of Fatty Acids in the Resolution of Autoimmune and Inflammatory Diseases",slug:"role-of-fatty-acids-in-the-resolution-of-autoimmune-and-inflammatory-diseases",signatures:"Elena Puertollano, María A. Puertollano, Gerardo Álvarez de Cienfuegos and Manuel A. de Pablo",authors:[{id:"35125",title:"Dr.",name:"Manuel Antonio",middleName:null,surname:"de Pablo",fullName:"Manuel Antonio de Pablo",slug:"manuel-antonio-de-pablo"},{id:"45341",title:"Dr.",name:"M. Angeles",middleName:null,surname:"Puertollano",fullName:"M. Angeles Puertollano",slug:"m.-angeles-puertollano"},{id:"45342",title:"Dr",name:"Elena",middleName:null,surname:"Puertollano",fullName:"Elena Puertollano",slug:"elena-puertollano"},{id:"45343",title:"Dr.",name:"Gerardo",middleName:null,surname:"Alvarez de Cienfuegos",fullName:"Gerardo Alvarez de Cienfuegos",slug:"gerardo-alvarez-de-cienfuegos"}]},{id:"20684",title:"Autoimmune Disorder and Autism",slug:"autoimmune-disorder-and-autism",signatures:"Xiaohong Li and Hua Zou",authors:[{id:"50228",title:"Dr.",name:"Xiaohong",middleName:null,surname:"Li",fullName:"Xiaohong Li",slug:"xiaohong-li"},{id:"50235",title:"Dr.",name:"Hua",middleName:null,surname:"Zou",fullName:"Hua Zou",slug:"hua-zou"}]},{id:"20685",title:"Chronobiology of and Chronotherapy for Rheumatoid Arthritis",slug:"chronobiology-of-and-chronotherapy-for-rheumatoid-arthritis",signatures:"Hideto To",authors:[{id:"45740",title:"Prof.",name:"Hideto",middleName:null,surname:"To",fullName:"Hideto To",slug:"hideto-to"}]},{id:"20686",title:"Four Aspects of Autoimmunity and How to Regain Tolerance to Self From an Autoimmune Disease Utilizing the Modified Vaccination Technique",slug:"four-aspects-of-autoimmunity-and-how-to-regain-tolerance-to-self-from-an-autoimmune-disease-utilizin",signatures:"Arpad Z. Barabas, Chad D. Cole, Arpad D. Barabas, Rene Lafreniere and Donald M. Weir",authors:[{id:"40002",title:"Dr.",name:"Arpad Z.",middleName:null,surname:"Barabas",fullName:"Arpad Z. Barabas",slug:"arpad-z.-barabas"},{id:"137145",title:"Dr.",name:"Chad",middleName:null,surname:"Cole",fullName:"Chad Cole",slug:"chad-cole"}]},{id:"20687",title:"Parasitic Helminths as Potential Therapeutic Agents Against Autoimmune Disorders",slug:"parasitic-helminths-as-potential-therapeutic-agents-against-autoimmune-disorders",signatures:"Yoshio Osada",authors:[{id:"44076",title:"Dr.",name:"Yoshio",middleName:null,surname:"Osada",fullName:"Yoshio Osada",slug:"yoshio-osada"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"71307",title:"Post-Transfusion Haemolytic Reactions",doi:"10.5772/intechopen.91019",slug:"post-transfusion-haemolytic-reactions",body:'\n
\n
1. Introduction
\n
Haemolytic transfusion reaction (HTR) is the result of accelerated destruction of red blood cells. The most common cause is immunological incompatibility between a donor and a blood recipient. It is mainly haemolysis that is responsible for the destruction of transfused donor blood cells by antibodies present in the recipient, but in rare cases, destruction may be caused in recipient blood cells by donor antibodies present in transfused plasma or platelet concentrate [1]. Haemolysis may also occur due to non-immunological reasons, such as thermal, osmotic or mechanical damage to the transfused blood; bacterial infection or extremely rare and blood transfusion from a donor with congenital haemolytic anaemia due to deficiency of glucose-6-phosphate dehydrogenase [2].
\n
\n
\n
2. The incidence of haemolytic transfusion reactions
\n
Currently, the incidence of haemolytic transfusion reactions is difficult to estimate. Most data come from retrospective studies that do not include reactions not reported by clinicians. In contrast, prospective studies also contain errors due to reaction symptoms often remaining unrecognised or masked by associated diseases, for example, bleeding or liver disease [1]. The frequency of reporting haemolytic transfusion reactions may also depend on other factors, such as patient population, transfusion response reporting system and medical staff education. Historical research results indicate that the frequency of haemolytic transfusion reactions falls between 1:10,000 and 1:50,000 transfused blood components [3, 4]. In contrast, the incidence for patients receiving a transfusion is estimated to be higher (about 1:500–1:800 patients) because most recipients receive more than one blood unit. It is worth noting that the estimation of the frequency of haemolytic reactions depends on the number of transfusions in a given centre. Thus, in large clinical centres, where severely ill patients are treated, more of these events are recorded [4]. A report issued by the Quebec Haemovigilance System covering 5 years of observation described 47 ABO incompatibility reactions, 55 cases of acute haemolytic transfusion reaction and 91 cases of delayed transfusion reaction in reference to 7059 all reported transfusion reactions. It was estimated that the frequency of reactions resulting from the ABO incompatibility was 1:27,318, acute haemolytic transfusion reactions 1:14,901 and delayed haemolytic transfusion reactions 1:9313 per unit of transfused red blood cell concentrate [5].
\n
The most common reaction among the acute (approximately 30%) was haemolysis resulting from ABO incompatibility [5]. In the annual report Serious Hazards of Transfusion (SHOT), published in England, in 2017, 42 haemolytic transfusion reactions were reported in reference to 3230 of all reactions observed following transfusion of blood components, of which 13 cases of acute haemolytic transfusion reaction and 29 cases of delayed haemolytic reaction (including 6 cases of hyperhemolysis) were reported. The number of reported cases of delayed haemolytic transfusion reaction was higher than in 2016, but comparable with previous years [6]. Factors that can affect the increase in the number of delayed haemolytic reactions include correctness in carrying out serological tests, longer survival of patients after transfusions and an increase in the number of transfused blood components. Since most patients receive more than one unit of red blood cell concentrate, the estimated incidence of delayed haemolytic transfusion reactions is from 1:854 to 1:524 per patient who has been transfused and is higher than per transfused unit [7]. In the population, delayed haemolytic transfusion reactions occur with a frequency of 1.69/100,000 per year [7].
\n
\n
\n
3. Mechanisms of haemolytic transfusion reactions
\n
Red blood cells undergo haemolysis in the intravascular mechanism, in blood or extravascular vessels, that is, organs involving cells of the reticuloendothelial system, primarily spleen and/or liver. Clinically significant differences between the above mechanisms of red blood cells destruction are based on the time of onset of haemolysis and the destruction rate of red blood cells. Intravascular haemolysis is characterised by the destruction of red blood cells at a rate of about 200 ml of transfused cells within 1 h of transfusion. It is manifested by a rapid decrease in haemoglobin, haemoglobinemia and haemoglobinuria and can potentially be life threatening [2]. In contrast, extravascular haemolysis is less dramatic, with a rate of destruction of red blood cells of approximately 0.25 ml/h/1 kg of recipient’s body weight. For example, for 70 kg recipient, about 18 ml of transfused red blood cells are destroyed per hour. However, it is worth noting that despite the low intensity of haemolysis, the survival time of red blood cells after transfusion is significantly reduced [2]. In general, intravascular haemolysis is called as an early acute haemolytic transfusion reaction. It can occur during transfusion or up to 24 h after transfusion of red blood cells. In comparison extravascular haemolysis is called delayed haemolytic transfusion reaction and usually occurs 24 h or days after the end of the transfusion. The quoted breakdown of reactions is somewhat artificial, because the symptoms associated with haemolytic reactions sometimes overlap [1]. The occurrence and severity of individual clinical symptoms can vary widely and are often non-specific [1, 8].
\n
Red blood cell transfusion can also stimulate the production of alloantibodies without the occurrence of haemolysis. This phenomenon is called delayed serologic transfusion reaction (DSTR) and should be differentiated from delayed haemolytic transfusion reaction [9].
\n
\n
3.1 Intravascular haemolysis
\n
Most often intravascular haemolysis is the result of the destruction of red blood cells by the complement system, stimulated by the presence of alloantibodies or autoantibodies. Among alloantibodies, such haemolysis is induced by anti-A and anti-B, rarely anti-Jka, anti-Jkb, anti-Vel, anti-P, anti-Lea and very unique antibodies with other specificities [10, 11]. In all these cases, haemolysis takes place via the classical pathway of complement activation. Its occurrence and severity, in addition to the class of antibodies, is also affected by the number of antigenic determinants with which the antibodies react. The reaction is most severe in the case of antigens A and B, because their number is estimated at about 5 × 105 per cell [12, 13]. In contrast, the presence of antigens from the Rh, Kell, Kidd and Duffy systems on the surface of red blood cells is determined in the range of 103–104 per cell [12]. Table 1 shows the number of antigenic determinants on the cell surface for selected red blood cell antigens.
\n
\n
\n
\n
\n\n
\n
Blood group system
\n
Antigens
\n
The number of antigenic determinants on the surface of the cell membrane
\n
\n\n\n
\n
ABO
\n
A1\n
\n
8.5 × 105\n
\n
\n
\n
A2\n
\n
2.5 × 105\n
\n
\n
\n
B
\n
7.5 × 105\n
\n
\n
\n
Rh
\n
D
\n
1–2 × 105\n
\n
\n
\n
C
\n
7–8 × 104\n
\n
\n
\n
e
\n
1.8–2.4 × 104\n
\n
\n
\n
Kell
\n
K
\n
6.1 × 103\n
\n
\n
\n
Duffy
\n
Fya\n
\n
1.7 × 104\n
\n
\n
\n
Kidd
\n
Jka\n
\n
1.4 × 105\n
\n
\n
\n
MNSs
\n
S
\n
1.2 × 104\n
\n
\n\n
Table 1.
Number of antigenic determinants on the cell surface of the red blood cell (according to [12, 13]).
\n
Antibodies combined with antigens by triggering the complement cascade lead to cell lysis. This mechanism is called the classic pathway for complement activation and is shown in Figure 1.
\n
Figure 1.
The classic pathway for complement.
\n
The starting point is the antigen-antibody complex present on the surface of the cell membrane [14, 15]. Antibodies of the IgM and IgG class (outside the IgG4 subclass) bind the C1q protein in the initial stage of activation. The condition for complement activation is the binding of the C1q molecule by two Fc fragments of adjacent IgG antibodies or by one IgM molecule. It should be noted here that the IgM class is more efficient in starting the process of complement activation than the IgG class [2, 15]. The C1qrs complex is created and activates the C2 and C4 components and their distribution into C2a and C2b as well as C4a and C4b. The C4b2a complex has proteolytic properties and is called C3 convertase. Convertase breaks down molecules of C3 into C3a, C3b, C3c and C3d. The C3b and C3d components bind with the red blood cell membrane and in many cases the complement cascade process ends. In other cases, the C3b component activates C5 and C5a and C5b are formed. C5b binds to C6, then to C7. This creates a complex of three C5b-6-7 particles, which is partially incorporated into the cell membrane and further binds C8. The C5b-8 complexes create holes in the cell membrane that increase when exposed to the C9 component. The C5B-C9 complex called membrane attack complex (MAC) creates pores in the cell membrane of a red blood cell that are 1/700 of its size. Haemoglobin escapes from the cells into the plasma, and the effects of haemolysis are visible macroscopically in the plasma of the blood sample [15].
\n
The alternative path of complement activation and the lectin path of complement activation do not play a role in the destruction of red blood cells. Although the mechanism of the lectin route may be the reason for the in vivo ineffectiveness of the use of monoclonal and recombinant antibodies, which are thus eliminated from the body before they fulfil their function, for example, anti-D Ig for prevention purposes in RhD maternal-foetal conflict [16].
\n
However, the complement system does not work specifically. The safety of body cells is enabled by factors that regulate complement activity present in plasma and on cells of various tissues, including red blood cells. Membrane inhibitor of reactive lysis (MIRL) (CD59) and decay accelerating factor (DAF) (CD55) are essential to protect red blood cells from haemolysis. The expression of these membrane inhibitors is associated with Cromer group system and CD59. On blood cells with the Cromer mull phenotype, known as Inab, DAF inhibitor expression is absent [17, 18]. DAF regulates C3a-converting activity. MIRL inhibits membrane attack complex [15, 17]. Lack of these particles may increase the susceptibility of red blood cells to intravascular haemolysis due to complement activation [19].
\n
\n
\n
3.2 Extravascular haemolysis
\n
In a situation in which, despite activation of the complement system, through antigen-antibody reaction, there is no intravascular haemolysis, red blood cells with detectable C3b component remain in the circulation. This kind of mechanism of red blood cell destruction occurs for IgG antibodies with complement system [13]. They may interact with CR1 and CR3 receptors on macrophages and consequently undergo phagocytosis. Most of the cells coated by the complement C3b component are destroyed by liver macrophages, that is, by Kupffer cells, while the cells coated with antibody molecules are mainly destroyed by spleen macrophages. They have surface receptors that recognise antibody classes and subclasses, and complement components, of which the Fc R1 receptor is specific for red cells coated with antibodies [1]. Blood cells connected to this receptor are destroyed in the process of antibody-dependent cytotoxicity. Red blood cells can be absorbed and completely “digested” inside the macrophage. They can also be partially absorbed and then the integrity of the cell membrane is disturbed by the loss of proteins and lipids, which changes its osmotic properties. Such a blood cell, after being released from the macrophage, circulates in the blood as a spherocyte, whose survival is short. The macrophage cytotoxins are another mechanism that plays a role in the destruction of red blood cells. As a consequence of antibody-dependent cell-mediated cytotoxicity (ADCC) haemoglobinemia and haemoglobinuria may occur similarly to intravascular haemolysis, although the antibodies that caused it do not bind complement components.
\n
\n
\n
\n
4. Mediators of inflammatory reactions in haemolytic transfusion reactions
\n
Receptors for complement activation products C3a and C5a are found on many cells: monocytes, macrophages, neutrophils, platelets, endothelium and smooth muscle. Their release causes an increase in the concentration of oxygen radicals, leukotrienes, nitric oxide and cytokines. The increase in cytokine release may also be due to the interaction of Fcγ R1 receptors with IgG molecules associated with red blood cells. Udani et al. [20] showed in vitro that in the case of ABO incompatibility, monocytes are directly involved in the formation of acute haemolytic transfusion reaction [15]. Incompatible red blood cells reduce CD14 expression and increase CD44 expression on monocytes in whole blood. After 24 incubations with incompatible red blood cells, monocytes show a significant increase in CD44 levels. The results of these studies indicate a critical role of monocyte activation in the development of intravascular haemolytic transfusion reaction [15].
\n
In ABO incompatibility, in which anti-A, anti-B and anti-AB antibodies activate complement leading to intravascular haemolysis, a large amount of tumour necrosis factor-α (TNF) and interleukins CXCL8 (IL-8) and CCL2 are released into the plasma (MCP-1) [19, 20, 21]. TNF-α is released first, its elevated concentration is already detected within first 2 h. It carries a pro-inflammatory potential that is responsible for fever, leukocyte activation, stimulation of procoagulant activity, increased antibody production and vascular wall permeability [22]. TNF-α also stimulates endothelial cells to synthesise adhesion molecules and chemotactic cytokines [22]. CXCL8 and CCL2 produced in the blood during ABO incompatibility will appear later than TNF-α in very high concentrations. CXCL8 primarily activates neutrophils, which leads to the accumulation of leukocytes in the lung vessels of small diameter and damage to the endothelium of blood vessels and their higher permeability [1, 12]. CCL2 is mainly a chemotactic and activating factor for monocytes [1, 12].
\n
In incompatibility, in which non-complement IgG antibodies cause extravascular haemolysis, cytokines belonging to two categories differing in response rates are produced: (1) synthesised at a concentration higher than 1 μg/ml within 24 h and (2) synthesised at a concentration of about 100 pg/ml. Low concentration cytokines include IL-1β, IL-6 and TNF-α. CXCL8 concentration is similar to that in intravascular haemolysis, whereas TNF-α is synthesised at low concentration, estimated at <100 pg/ml [1, 2]. IL-1ra (receptor antagonist) is produced in extravascular haemolysis, which is an IL-1 receptor antagonist. Its presence to some extent affects some clinical differences between extravascular and intravascular haemolysis [23]. IL-1β concentration and IL-6 produced by monocytes in response to red blood cells coated with IgG antibodies increase progressively within 24 h to a concentration of 100 pg/ml. Since IL-1β and IL-6 affect proliferation and differentiation of β-lymphocytes, the synthesis of these two cytokines enhances the synthesis of allo- and autoantibodies, which are often involved in the formation of delayed haemolytic transfusion reaction [1, 24, 25].
\n
\n
\n
5. Complications of haemolytic transfusion reactions
\n
\n
5.1 Disseminated intravascular coagulation associated with haemolytic transfusion reaction
\n
The key pathogenetic phenomenon in DIC is excessive thrombin generation in the tissue factor (TF)-dependent pathway and activated factor VII (FVIIa-activated factor VII) [26]. In the pathogenesis of DIC, interactions between the blood coagulation system and mediators of the inflammatory response are also of great importance [27]. Proinflammatory cytokines affect blood coagulation and fibrinolysis, for example, TNF-α and IL-1 increase TF expression and inhibit thrombomodulin (TM) expression on vascular endothelial cells [28]. On the one hand, these processes lead to the production of a large amount of thrombin that converts fibrinogen to fibrin. Fibrin creates blood clots in the light of small vessels trapping the platelets. If the activation of coagulation is not timely inhibited, the resulting clots will block the blood supply to vital organs, which will be manifested in their failure. On the other hand, the formation of a large amount of blood clots will “consume” blood coagulation factors and platelets, which will manifest as a haemorrhagic diathesis. In addition, their degradation products (fibrinogen/fibrin degradation products (FDP)) resulting from the breakdown of fibrinogen and fibrin exhibit anticoagulant properties, inhibit platelet function, act as cytotoxic vascular endothelium and increase capillary permeability, further disrupting haemostasis mechanisms [26].
\n
Clinically, this is manifested by unexpected bleeding and/or a decrease in blood pressure. The course is acute, dynamic, with thrombocytopenia, increased concentration of fibrin degradation products, prolonged prothrombin time (PT), extended partial thromboplastin time after activation (activated partial thromboplastin time (APTT)) and hypofibrinogenaemia. Table 2 presents the point algorithm for the diagnosis of acute disseminated intravascular coagulation.
\n
\n
\n
\n
\n\n
\n
Test
\n
Result
\n
Score
\n
\n\n\n
\n
Platelet count (×109/l)
\n
>100
\n
0
\n
\n
\n
>50, ale ≤ 100
\n
1
\n
\n
\n
≤50
\n
2
\n
\n
\n
Concentration of fibrinogen/fibrin degradation markers (FDP; D-dimery)
\n
Normal
\n
1
\n
\n
\n
Moderate
\n
2
\n
\n
\n
Growth significant increase
\n
3
\n
\n
\n
Prothrombin time extended
\n
o < 3 s
\n
0
\n
\n
\n
o ≥ 3 s, ale < 6 s
\n
1
\n
\n
\n
o ≥ 6 s
\n
2
\n
\n
\n
Fibrinogen concentration (g/l)
\n
>1.0
\n
0
\n
\n
\n
≤1.0
\n
1
\n
\n
\n
DIC acute diagnosis
\n
≥5
\n
\n
\n\n
Table 2.
Point algorithm for the diagnosis of acute disseminated coagulation Intravascular [29, 30, 31].
\n
However, this complication is rare and predominantly accompanies intravascular haemolysis, but in recipients who have received non-compliant blood in the ABO system, it occurs even in 25% of cases [1].
\n
\n
\n
5.2 Hypotension and shock
\n
Hypotension occurs in about 1 in 10 cases of intravascular haemolytic transfusion reaction, but is also sometimes observed in extravascular haemolysis. Complement activation appears to be the most important determining factor in these cases. During the haemolytic reaction, C3a, C4a, C5a and C5a-des-arg anaphylatoxins are released. Furthermore, consumption of a C1-esterase inhibitor contributes to the activation of the kinin pathway associated with the release of bradykinin [32]. In addition, tumour necrosis factor (TNF) and interleukin-1 (IL-1), released by phagocytes during haemolytic transfusion reaction may also contribute to hypotension and shock [32].
\n
\n
\n
5.3 Impaired renal function
\n
Impaired renal function is observed in both intravascular and extravascular haemolytic transfusion reactions, although definitely more frequently in the case of intravascular. The severity of this abnormality varies greatly—from asymptomatic increase in urea (BUN) and serum creatinine up to complete anuria. Concomitant hypotension and intravascular coagulation syndrome may increase renal impairment. Blood clots that form in the renal arterioles cause cortical kidney attacks. Haemoglobin released from red blood cells also reacts nephrotoxically with nitric oxide (NO), damaging the epithelial cells of the renal tubules and the stroma that remains after their breakdown [33, 34].
\n
Intravascular haemolysis modulates blood pressure and local blood flow through changes in the metabolism of the physiological vasodilator—nitric oxide (NO). NO can bind to thiol groups and haemoglobin haeme [35]. The connection of NO with haeme Fe2+ impairs oxygen transport through Hb. The presence of O2 leads to oxidation of NO to NO3 and oxidation of Fe2+ to Fe3+ and the formation of methaemoglobin. The interaction between Hb and NO is regulated by the allosteric transition of haemoglobin R (oxyHb) to the T form (deoxyHb). In oxyHb, cysteine is exposed at position 93 of the haemoglobin amino acid chain (Cys 93β). It is known that a significant proportion of NO does not immediately bind to HbFe2+ heme, instead it binds to cysteine, resulting in the formation of the S-nitrosothiol derivative Hb (SNO-Hb). This process is reversible, so SNO-Hb releases NO, which is transported to endothelial receptors, where it participates in the regulation of vascular wall tone and blood flow. In the case of haemolysis of red blood cells, the free haemoglobin released from them reacts with NO much faster and more strongly than Hb inside cells [35]. The effect of intravascular haemolysis described above may be very similar to the side effect caused by transfusion of first-generation stromal haemoglobin solutions. This has been tested for its use as a substitute for red blood cells. It had vasoconstrictive and, as a result, hypertensive effect. This effect is largely attributed to the binding nitric oxide by free haemoglobin (NO) [36].
\n
\n
\n
\n
6. Clinical symptoms of transfusion haemolytic reactions
\n
Intravascular haemolysis is accompanied by haemoglobinaemia and usually also haemoglobinuria, whereas extravascular haemolysis can only be accompanied by anaemia. In both cases, the patient’s serum bilirubin increases, but it depends on the degree of haemolysis as well as liver function [1]. Elevated LDH is always observed with intravascular haemolysis, not always with extravascular haemolysis. Reduced haptoglobin levels usually occur in both types of haemolysis. Drop in blood pressure is much more common in patients with intravascular than extravascular haemolysis. Renal failure and DIC are also more commonly associated with intravascular haemolysis. Some patients may experience organ failure such as the pancreas, heart and even multiple organ failure that threatens the patient’s life.
\n
In unconscious patients and patients under general anaesthesia, it may be difficult to recognise a haemolytic transfusion reaction, as some symptoms may go unnoticed (e.g. pain and nausea). Pain, which is described as a symptom of haemolytic reactions, is located at the puncture site, back, chest, groin and head. The occurrence of pain in the haemolytic transfusion reaction is not clear. It is probably the result of direct stimulation of nociceptive nerves in perivascular tissue by bradykinin, which, in turn, is released during sudden activation of complement [37]. Clinical manifestations are shown in Table 3.
\n
\n
\n
\n\n
\n
Initial symptoms of haemolytic transfusion reactions
\n
Complications
\n
\n\n\n
\n
Intravascular haemolysis Nausea or vomiting Ache Dyspnoea Decrease in RR and/or tachycardia Dark urine
Initial symptoms of haemolytic transfusion reactions.
\n
\n
\n
7. Causes of haemolytic transfusion reactions
\n
\n
7.1 Haemolytic transfusion reactions caused by alloantibodies
\n
The most common cause of haemolytic transfusion reactions is the immunological destruction of red blood cells resulting from the reaction of antibodies in the recipient’s blood and the antigens present on the transfused donor’s blood cells to which these antibodies are made.
\n
Antibodies capable of destroying transfused blood cells are called clinically relevant antibodies, and the transfusion reaction in the event of immunological incompatibility depends on: (1) specificity of antibodies; (2) thermal amplitude of the antibodies; (3) IgG classes and IgG subclasses; (4) number, density and spatial configuration of antigenic sites on red blood cells; (5) the ability of antibodies to activate the complement system; (6) plasma concentrations of antibodies and (7) volumes of transfused red blood cells. A very important feature of all antibodies responsible for causing a haemolytic transfusion reaction is its in vitro activity at 37°C.
\n
Antibodies detected at a lower temperature are not considered clinically relevant, for example, anti-A1, anti-M and anti-P1, whose optimal reaction is usually at low temperature, but if detected at 37°C, they can cause destruction of red blood cells with the appropriate antigen. They then become clinically significant.
\n
Features of antibodies (specificity, class and heat amplitude) and antigens (density of antigenic sites and their distribution) against which the antibodies directed are interconnected. In different people, antibodies with a particular specificity most often occur in the same class of immunoglobulins and have a similar heat amplitude, for example, anti-A, anti-B and anti-AB from the ABO system often belong to both IgM and IgG classes, they bind complement and have an extended thermal amplitude of up to 37°C.
\n
A and B antigens are highly immunogenic. Anti-A, anti-B and anti-AB antibodies are involved in causing an early intravascular transfusion reaction, and transfusion of incompatible blood in the ABO system poses a threat to the recipient’s life, especially when group A red blood cells are transfused to a patient with group O. Sixty-one (61%) of all haemolytic transfusion-related fatal reactions are associated with the ABO incompatibility [38, 39]. A contrasting example is the Lua antigen and anti-Lua antibodies. They are usually IgM molecules, are rarely active at 37°C and usually do not bind complement. Lua antigens have uneven distribution on red blood cells and are weakly immunogenic. No cases of acute haemolytic reaction caused by anti-Lua antibodies have been reported, delayed transfusion haemolytic reaction is rare and occurs only in mild form.
\n
Not all detectable alloantibodies that react with red blood cells can cause a haemolytic reaction. The specificity of the antibodies potentially responsible for intravascular and extravascular haemolysis is shown in Table 4.
\n
\n
\n
\n
\n\n
\n
Blood group system
\n
Intravascular haemolysis
\n
Extravascular haemolysis
\n
\n\n\n
\n
ABO, H
\n
Anti-A, -B, -AB, -H in the Bombay phenotype
\n
\n
\n
\n
Rh
\n
\n
All
\n
\n
\n
Kell
\n
Anti-K
\n
All
\n
\n
\n
Kidd
\n
Anti-Jka\n
\n
Anti-Jka, -Jkb, -Jk3\n
\n
\n
\n
Duffy
\n
\n
Anti-Fya, -Fyb\n
\n
\n
\n
MNS
\n
\n
Anti-M, -S, -s, -U
\n
\n
\n
Lutheran
\n
\n
Anti-Lub\n
\n
\n
\n
Lewis
\n
Anti-Lea\n
\n
\n
\n
\n
Cartwright
\n
\n
Anti-Yta\n
\n
\n
\n
Vel
\n
Anti-Vel
\n
\n
\n
\n
Colton
\n
\n
Anti-Coa\n
\n
\n
\n
Dombrock
\n
\n
Anti-Doa, -Dob\n
\n
\n\n
Table 4.
Specificity of selected antibodies associated with haemolytic transfusion reactions.
\n
Similar reactions to anti-A and anti-B come from anti-PP1Pk, anti-P1 and anti-Vel. Other antibodies cause intravascular haemolysis, but sometimes they may be accompanied by intravascular haemolysis. Such reactions were observed in the following blood group systems: Rh, MNSs, Lutheran, Kell, Duffy, Diego and Lewis. The mechanism of appearance of intravascular symptoms has not been fully explained, because although some of the antibodies bind complement components, their reactions end with C3 components. Only in the case of rare haemolytic reactions due to anti-Lea it was shown that the coated cells are destroyed by the spleen macrophages very slowly and in the event of transfusion of large volumes of red blood cells, they become inefficient. Then intravascular haemolysis coincides with visible haemoglobinuria [40, 41]. Interesting clinical point of view are antibodies from the Kidd system. They activate the complement system to the stage of binding of the C3b component, causing extravascular haemolysis. However, the symptoms in some recipients, or the occurrence of a reaction already during a blood transfusion and haemoglobinuria, indicate that the destruction of blood cells also takes place inside the vessel. In the laboratory setting, anti-Jka antibodies are called “insidious” antibodies because they are often difficult to detect due to their low concentration, and yet they can cause a severe haemolytic complication [41].
\n
Patients with antibodies found to be clinically insignificant may theoretically be given a blood transfusion from a donor with the antigen to which they are directed. In clinical practice, however, such antibodies can sometimes destroy donor blood cells. Therefore, if possible, blood without this antigen should be selected [41].
\n
Another cause for haemolytic transfusion reaction may be a secondary immune response in patients who have developed alloantibodies during previous transfusions of blood components or pregnancy. This is called delayed haemolytic transfusion reaction (DHTR) in which current blood transfusion stimulates memory lymphocytes and stimulates the production of alloantibodies directed at incompatible antigen found on transfused blood cells [21, 42]. In approximately 50% of cases, alloantibodies produced after transfusion or pregnancy cease to be detected after a few months, and this period of time depends on the specificity of the antibodies and the individual characteristics of the immune system. Schonewille et al. found that, using current laboratory methods, 25% of red blood cell antibodies become indeterminate on average after about 10 months from production [43]. Therefore, pre-transfusion tests may not always detect the presence of antibodies. Antibodies stimulated for synthesis may cause symptoms of haemolysis after 3–10 days, usually very mild and their presence can be detected after 10–21 days. Table 5 presents features of delayed haemolytic transfusion reaction and the time of their occurrence.
\n
\n
\n
\n
\n\n
\n
Time (days)
\n
Occurrence
\n
Explanation
\n
\n\n\n
\n
0
\n
Negative pre-transfusion test
\n
Antibody titres below detection threshold
\n
\n
\n
1
\n
Red blood cell transfusion
\n
\n
\n
\n
3–10
\n
Clinical symptoms of haemolysis
\n
Acceleration of transfused blood cells destruction
\n
\n
\n
10–21
\n
Post-transfusion testing of blood samples: DAT and screen of antibodies positive
\n
Increase in antibody titre; donated blood cells coated with antibodies
\n
\n
\n
>21
\n
DAT can be negative
\n
Destruction of donor blood cells in reticuloendothelial system and/or liver
\n
\n
\n
>21–300
\n
DAT may be positive, eluate testing may show presence of alloantibodies or panagglutination
\n
Alloantibodies not specifically associated with autologous red blood cells or produced warm antibodies
\n
\n\n
Table 5.
Features of late hemolytic transfusion reaction and time of their occurrence [21].
DAT—direct antiglobulin test.
\n
Antibodies that cause a delayed haemolytic transfusion reaction are IgG molecules that are binding or non-binding for complementary components. Their specificity is most often directed to the antigens of the Rh, Kidd, Duffy, MNS and Kell systems [14]. In approximately 11% of cases, more than one antibody specificity is detected. In rare cases, the result of transfusion alloimmunity in DHTR may be the production of autoantibodies (warm IgG autoantibodies or cold autoagglutinins). This phenomenon occurs in patients with sickle cell disease [44, 45, 46].
\n
\n
\n
7.2 Haemolytic transfusion reactions due to passive transmission of alloantibodies in blood components or in blood products
\n
Transfusion of plasma, platelet or granulocyte concentrate from donors incompatible in the ABO system with the recipient may lead to acute haemolytic transfusion reaction and even death. The severity of the reaction depends on the titre of anti-A and/or anti-B antibodies in the transfused plasma or in the blood component containing the plasma, and on its volume [47, 48, 49]. Tests on the ABO system titre in group O apheresis concentrates of platelets show that 26% of samples have an anti-A or anti-A, B antibody titre of 64 or higher. This concentration may be responsible for causing a haemolytic reaction [50]. In turn, the results of studies by Coolig et al. [51] carried out in pooled platelet concentrates of whole blood groups showed that 60% of them had anti-A titres of at least 64 [51]. Repeated transfusions of ABO incompatible platelet concentrate may lead to accumulation of anti-A antibodies in the recipient’s plasma, which may result in severe haemolytic reactions [52]. Unfortunately, despite many studies, it has not been possible to determine the critical titre of anti-A and/or anti-B antibodies that would be safe in the event of transfusion of ABO incompatible platelet concentrates, and in many countries, proprietary haemolysis prevention programs have been developed for recipients of incompatible platelets [48, 49, 50, 53].
\n
Haemolytic transfusion reactions due to passively transferred anti-A and/or anti-B antibodies have also been observed in patients after intravenous immunoglobulin administration [54]. Spath et al. [55] analysed reports available in the literature describing cases of haemolysis in patients treated with intravenous immunoglobulins [55]. They showed that the haemolytic reaction is induced by IgG anti-A/B antibodies present in immunoglobulin products. The reaction generally occurs in high-dose IVIG recipients [55].
\n
\n
\n
7.3 Haemolytic reaction associated with the “bystander immune cytolysis”
\n
The haemolytic transfusion reactions may have a different immunological origin than the reactions of antibodies in the recipient’s blood and the antigen present on the donor’s blood cells. This additional mechanism occurs when recipient’s red blood cells are destroyed by a reaction called “bystander immune cytolysis”. It is defined as the immunological destruction of red blood cells by antibodies whose specificity corresponds to antigens found on other cells/blood cells (e.g. HLA antigens found on leukocytes and plasma proteins), while red blood cells are only close to this immunological “confusion” [56]. They are destroyed by the complement system, although they did not participate directly in the antigen-antibody reaction. One of the reasons for this haemolytic reaction is the binding of the C567 complement complex, activated in an immune reaction, to the membrane of red blood cells not participating in the reaction but located in the vicinity [56]. Blood cells are destroyed as a result of the activation of the binding of the remaining components of C8 and C9 complement and the formation of the MAC complex on the blood cells [56]. The mechanism of “bystander” haemolysis is similar to the destruction of blood cells in patients with paroxysmal nocturnal haemoglobinuria [57, 58]. A characteristic feature of the cell membrane of these blood cells is the lack or weak expression of the CD55 (DAF) and CD 59 (MIRL) proteins, which are complement inhibitors. This makes the subject more susceptible to haemolysis. It was found that when red blood cells became the “bystander” of leukocyte reactions and antibodies directed to them, they underwent haemolysis. The reaction of anti-HLA antibodies with leucocytes caused complement activation, which resulted in haemolysis of the patient’s red blood cells sensitive to the complement [59]. It is noteworthy that in patients with a haemolytic reaction associated with the immune cytolysis of the “bystander” not only transfused red blood cells but also autologous blood cells of the patient were destroyed.
\n
\n
\n
\n
8. Differentiation
\n
Early haemolytic transfusion reactions should be differentiated with septic shock due to bacterial contamination of the blood component, as well as anaphylaxis and bleeding. In addition, immune haemolysis of nocturnal paroxysmal haemoglobinuria or autoimmune anaemia should also be considered. The cause of an early haemolytic reaction may also be congenital haemolytic anaemia, for example, glucose-6-phosphate dehydrogenase deficiency or microangiopathic haemolytic anaemia (TTP, HUS and HELLP). In differential diagnosis, attention should also be paid to non-immune reasons related to improper blood storage, transfusion of red blood cells through a small needle diameter, etc.
\n
Differential diagnosis of delayed haemolytic transfusion reactions includes latent sources of infection, autoimmune haemolytic anaemia, cold agglutinin disease, nocturnal paroxysmal haemoglobinuria, bleeding, mechanical destruction of red blood cells, for example, artificial heart valves and TTP.
\n
It should be noted that an increase in body temperature and white blood cell count, typical for DHTR, can be interpreted as a sign of infection. In some patient groups, it may be difficult to recognise a delayed haemolytic transfusion reaction. Patients with liver failure are a special problem. Haemoglobinemia is not diagnosed in the serum of these patients due to jaundice, often direct antiglobulin reaction (DTA) is positive and elevated bilirubin and LDH are found.
\n
Another group are patients with absorbing haematomas. They may be similar to delayed haemolytic reactions. Elevated unbound bilirubin, LDH and decreased haptoglobin are observed. The presence of fibrinogen degradation products from an absorbing haematoma can be interpreted as a DIC symptom. DHTR can be identified in these patients by the presence of antigen on the transfused red blood cells to which the antibodies may be directed. Table 6 presents the differential diagnosis of haemolytic transfusion reactions.
\n
\n
\n\n
\n
\n
Alloantibodies responsible for haemolysis
Delayed serological transfusion reaction
Autoimmune haemolytic anaemia
Cold agglutinins disease
Non-immune haemolysis
use of inappropriate fluids
improper storage of blood components
defects in the blood-heating devices
needle diameter too small, haematocrit of transfused red blood cells too high
an inappropriate method of freezing/thawing red blood cells
using the wrong infusion pumps
bacterial infection of blood components
mechanical damage to blood cells, artificial valves
Congenital haemolytic anaemia
Haemoglobinopathies
Drug-induced haemolysis of red blood cells
Microangiopathic haemolytic anaemia
thrombocytopenic thrombosis (TTP)
haemolytic uremic syndrome
HELLP syndrome
Bleeding
Nocturnal paroxysmal haemoglobinuria
Polyagglutination
Infections
\nClostridium perfringens\n
Malaria
Babesiosis
\n
\n
\n\n
Table 6.
Differential diagnosis of haemolytic transfusion reactions [1].
\n
\n
\n
9. Diagnosis of transfusion haemolytic reactions
\n
If a haemolytic transfusion reaction is suspected, medical personnel should immediately stop transfusing a blood component. The blood unit should be checked at the patient’s bedside, whether it was properly administered. Often, the clinical manifestations of haemolytic reactions are not clear, and the cause of the complication should be differentiated with bacterial infection. Therefore, prior to conducting laboratory tests of donor blood, bacteriological examination of the component remaining after the transfusion cessation should be conducted.
\n
\n
9.1 Tests carried out in case of suspected early hemolytic transfusion reaction
\n
Laboratory tests—mainly serological—are crucial for the diagnosis of an early haemolytic reaction. The type of laboratory tests performed for early transfusion haemolytic reactions is shown in Table 7.
\n
\n
\n
\n\n
\n
Blood product
\n
Confirm ABO, Rh Confirm other antigen types, if indicated
\n
\n
\n
Blood bank laboratory
\n
Direct antiglobulin test (DAT) Confirm ABO, RH, antibody screen and identification Post-transfusion haemolysis check
Type of laboratory tests and the location of their performance in the case of early transfusion reaction.
\n
The basic serological examination consists of direct antiglobulin testing (DAT); determination of blood group and RhD in donor and recipient; repetition of the serological compliance test. A test should be performed for the presence of antibodies in the recipient before and after the transfusion. Positive DAT indicates haemolysis of red blood cells of immunisation origin. A negative DAT result does not exclude haemolysis, it may mean that the transfused blood cells have been destroyed by alloantibodies or the method used is not very sensitive. Alvarez et al. [60] compared the sensitivity of DAT performed by technique using monospecific IgG antiglobulin, flow cytometry and antibody elution. The study showed that DAT could only indicate 10% of antibody coated cells [61]. Performing DAT in the red blood cell eluate, its sensitivity was 1%. Flow cytometry proved to be a similarly sensitive method.
\n
The re-determination of the ABO and RhD blood group of the recipient before and after the transfusion and in the donors’ blood will exclude errors in the identification of the recipient or blood sample (wrong blood in tube (WBIT)). Test results carried out by Biomedical Excellence for Safer Transfusion Working Party of The International Society for Blood Transfusion in 10 countries with 62 institutions, which examined a total of 690,000 blood samples, showed that the frequency of WBIT is 1 in 165. In two countries, Sweden and Finland, which have implemented national identification systems, this frequency was 1 for 1986 samples [61].
\n
All-antibody screening for recipients is generally performed using routine testing on standard blood cells. A panel of standard cells should contain clinically important antigens in a homozygous form to detect the presence of weak antibodies. The test should be performed on serum/plasma samples taken before and after transfusion. If positive results indicate alloantibodies are present, they should be identified. Detection of a specific antigen on the donor’s blood cells is the confirmation that the detected alloantibodies were responsible for the haemolytic transfusion reaction. If negative results are obtained, additional tests should be performed, for example, PTA PEG, polybrene test and PTA NaCl test. If negative results persist, the test should be repeated after a week and after 2 weeks, as in some patients, the antibodies may have been consumed to destroy transfused incompatible red blood cells.
\n
Laboratory tests that help to differentiate haemolysis include determination of free haemoglobin in the blood and urine, haptoglobin and lactate dehydrogenase (LDH) and bilirubin. While interpreting the obtained test results, it should be kept in mind that haemolysis or shortening the survival time of red blood cells can be caused by non-immunological factors, for example, adding hypotonic fluids to red blood cells, inefficient heating or freezing devices, etc. [62]. Table 8 presents changes in laboratory indicators in transfusion haemolytic reactions [56].
Changes in laboratory indicators in haemolytic transfusion reactions [56].
Negative DAT mainly associated with HTR in ABO incompatibility.
IHTR vs. DHTR.
\n
\n
\n
9.2 Tests carried out in case of suspected delayed haemolytic transfusion reaction
\n
Laboratory tests show anaemia, increased LDH and bilirubin, decreased haptoglobin and higher white blood cell counts in post-transfusion haemolytic reactions. Bilirubin concentration depends on the severity of haemolysis and liver function.
\n
Serological tests show positive DAT and the presence of all red blood cell antibodies that were not detected prior to transfusion. This means that after transfusion of red blood cells, the production of alloantibodies directed to the antigen found on the transfused blood cells occurs.
\n
Positive DAT with anti-IgG reagents or with anti-IgG and anti-C3 reagents is generally seen as two red blood cell populations. It has been observed that in some patients, the coating of blood cells includes not only transfused, but also autologous red blood cells. Positive DAT with anti-IgG and anti-C3d reagents may persist for several months [9].
\n
Alloantibody testing should be performed in the intermediate antiglobulin test (IAT) and enzyme test. In both methods, in addition to the reference blood cells, the patient’s autologous blood cells should be included. Depending on the specificity, alloantibodies responsible for the delayed transfusion reaction activate in characteristic tests, for example, antibodies from the Rh system react in an enzymatic test, often also in anti-globulin testing. In contrast, anti-K, anti-Fya antibodies react in an anti-globulin test. Positive reactions with allogeneic blood cells are accompanied by positive auto control of the patient’s red blood cells. Ness et al. [9] showed that the formation of warm autoantibodies after the onset of DHTR is relatively common. Approximately one-third of patients who were examined 25 days after the onset of the reaction presented a positive DAT due to autoantibodies with broad specificity [9]. The incidence of autoantibodies after DHTR may be even higher because autoantibodies may mimic the specificity of alloantibodies.
\n
Usually, plasma alloantibodies are detectable at 4–7 days after the transfusion and reach maximum activity between 10 and 15 days after the transfusion. When examining recipient red blood cells using a diagnostic reagent with a specificity corresponding to alloantibodies detected in the patient, mixed agglutination is observed, which indicates the presence of two blood cell populations in the patient’s circulation. One of them, which does not react with diagnostic antibodies, is the recipient’s autologous blood cells, the other population is antigenically incompatible transfused donor cells, not yet removed from the recipient’s circulation.
\n
\n
\n
\n
10. Treatment of transfusion haemolytic reactions
\n
Treatment of early haemolytic transfusion reactions depends mainly on the patient’s condition, which must be closely monitored. It is most important to observe the clinical symptoms of the recipient and stop the blood transfusion at the right moment. Particular attention should be paid to the patient’s circulation. In the event of a marked decrease in blood pressure, make-up fluids should be transfused and pressure amines should be administered. However, it is important to avoid overloading the circulation with fluids, especially in patients with heart or kidney failure. Catheterisation of the pulmonary artery helps to monitor the situation.
\n
In some cases, an exchange transfusion should be considered, bearing in mind that the haemolysis intensity depends mainly on the volume of incompatible blood transfused. For exchange transfusion, red blood cells without an antigen should be used against which the patient has developed alloantibodies. The decision to carry it out must be balanced and the course carefully monitored. It should be emphasised that in patients with an early reaction due to ABO incompatibility, exchange transfusion may reduce the risk of serious complications or death. For patients with ongoing haemorrhage choosing a blood for transfusion may be difficult. However, it should be remembered that these difficulties must not cause risk of haemorrhage. Often the way out of this situation is transfusion of O RhD negative red blood cells.
\n
The prevention of renal failure is aided by an early prevention of hypotension. A fluid balance should be maintained, the use of dehydrating agents (mannitol and furosemide) is helpful, but their oliguria should be closely monitored. Low doses of dopamine (1–5 μg/kg/min) may be used to maintain renal circulation, but this may not be effective.
\n
Treatment and prevention of DIC during haemolytic transfusion reaction is controversial. Heparin is recommended because it additionally acts as an inhibitor of the complement activity and limits haemolysis. However, there is a danger of bleeding. Another method of treating early haemolytic transfusion reaction is to use a high dose of 0.4/kg intravenous immunoglobulin per 24 h after blood transfusion.
\n
Delayed haemolytic transfusion reactions are well tolerated by most patients. Additional fluid and diuretic therapy are usually not necessary. Depending on the severity of the anaemia, transfusion of blood components should be avoided until the antibodies responsible for the reaction have been identified and the appropriate selection of blood cells has been made. Attempts have been made to use high doses of intravenous immunoglobulins to prevent haemolytic reactions in patients who have been immunised for winter and for whom compatible red blood cells have not been selected [63]. The main procedure for subsequent transfusions is to select red cells that do not contain the antigen for which all antibodies have been detected. Table 9 summarises the treatment options used in haemolytic transfusion reactions.
11. Prevention of haemolytic transfusion reactions
\n
Data on the incidence of haemolytic transfusion reactions vary from country to country and change over time. There are several causes. One of them was the use of improved techniques for detecting clinically relevant alloantibodies, which reduce the number of haemolytic transfusion reactions observed in blood recipients. In addition, the widespread introduction of automation and computerisation to pre-transfusion studies, which significantly limits the possibility of errors in serology laboratories and blood banks.
\n
The above improvements, however, did not significantly affect the elimination of mistakes made in hospitals leading to transfusion of inappropriate blood to the patient. These include, among others, errors in collecting blood samples from patients and blood transfusions to a wrong patient. These errors are the most common cause of ABO incompatible transfusions, threatening the patient’s life.
\n
The introduction of haemovigilance transfusiological surveillance systems has enabled the analysis of all fatal and severe transfusion reactions. It allows to identify malfunctioning procedures leading to transfusion reactions. It enforces the introduction of procedures eliminating further errors.
\n
\n
\n
12. Summary
\n
Preventing haemolytic transfusion reactions by focusing on advances in serology and transfusion medicine has significantly reduced their incidence. Progress in understanding reaction pathophysiology has helped clinically assess patients and treat them effectively. It is possible that technological progress enabling modification of red blood cells and the use of red blood cell substitutes will significantly change transfusion practice in the future and eliminate the occurrence of haemolytic transfusion reactions. But until then, HTRs will remain the most important adverse post-transfusion reaction.
\n
\n\n',keywords:"haemolytic reaction, haemolysis, transfusion reaction, HTR",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/71307.pdf",chapterXML:"https://mts.intechopen.com/source/xml/71307.xml",downloadPdfUrl:"/chapter/pdf-download/71307",previewPdfUrl:"/chapter/pdf-preview/71307",totalDownloads:205,totalViews:0,totalCrossrefCites:0,dateSubmitted:"June 11th 2019",dateReviewed:"January 6th 2020",datePrePublished:"March 3rd 2020",datePublished:"February 17th 2021",dateFinished:"March 3rd 2020",readingETA:"0",abstract:"Haemolytic post-transfusion reaction is caused by accelerated destruction of erythrocytes by immunological incompatibility between the donor and the recipient. It also occurs for non-immunological reasons: thermal, osmotic or mechanical damage and bacterial infection. Haemolysis can be endogenous (usually acute) and exogenous with macrophages in the reticuloendothelial system of spleen or liver (delayed). The pathophysiology: antibody binding erythrocyte antigens, antibody-coated erythrocytes interaction with monocytes/macrophages activating phagocytosis or antibody-dependent cytotoxicity and the production of inflammatory mediators. Antibodies destroying transfused blood cells are called clinically relevant antibodies that are active in vitro at 37°C. An interesting mechanism is the “bystander immune cytolysis”.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/71307",risUrl:"/chapter/ris/71307",signatures:"Jolanta Korsak and Anna Piotrowska",book:{id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,fullTitle:"Human Blood Group Systems and Haemoglobinopathies",slug:"human-blood-group-systems-and-haemoglobinopathies",publishedDate:"February 17th 2021",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"307983",title:"Associate Prof.",name:"Jolanta",middleName:null,surname:"Korsak",fullName:"Jolanta Korsak",slug:"jolanta-korsak",email:"jkorsak@wim.mil.pl",position:null,institution:null},{id:"310849",title:"BSc.",name:"Anna",middleName:null,surname:"Piotrowska",fullName:"Anna Piotrowska",slug:"anna-piotrowska",email:"apiotrowska@wim.mil.pl",position:null,institution:null}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. The incidence of haemolytic transfusion reactions",level:"1"},{id:"sec_3",title:"3. Mechanisms of haemolytic transfusion reactions",level:"1"},{id:"sec_3_2",title:"3.1 Intravascular haemolysis",level:"2"},{id:"sec_4_2",title:"3.2 Extravascular haemolysis",level:"2"},{id:"sec_6",title:"4. Mediators of inflammatory reactions in haemolytic transfusion reactions",level:"1"},{id:"sec_7",title:"5. Complications of haemolytic transfusion reactions",level:"1"},{id:"sec_7_2",title:"5.1 Disseminated intravascular coagulation associated with haemolytic transfusion reaction",level:"2"},{id:"sec_8_2",title:"5.2 Hypotension and shock",level:"2"},{id:"sec_9_2",title:"5.3 Impaired renal function",level:"2"},{id:"sec_11",title:"6. Clinical symptoms of transfusion haemolytic reactions",level:"1"},{id:"sec_12",title:"7. Causes of haemolytic transfusion reactions",level:"1"},{id:"sec_12_2",title:"7.1 Haemolytic transfusion reactions caused by alloantibodies",level:"2"},{id:"sec_13_2",title:"7.2 Haemolytic transfusion reactions due to passive transmission of alloantibodies in blood components or in blood products",level:"2"},{id:"sec_14_2",title:"7.3 Haemolytic reaction associated with the “bystander immune cytolysis”",level:"2"},{id:"sec_16",title:"8. Differentiation",level:"1"},{id:"sec_17",title:"9. Diagnosis of transfusion haemolytic reactions",level:"1"},{id:"sec_17_2",title:"9.1 Tests carried out in case of suspected early hemolytic transfusion reaction",level:"2"},{id:"sec_18_2",title:"9.2 Tests carried out in case of suspected delayed haemolytic transfusion reaction",level:"2"},{id:"sec_20",title:"10. Treatment of transfusion haemolytic reactions",level:"1"},{id:"sec_21",title:"11. Prevention of haemolytic transfusion reactions",level:"1"},{id:"sec_22",title:"12. Summary",level:"1"}],chapterReferences:[{id:"B1",body:'\nDavenport RD. Hemolytic transfusion reactions. In: Simon L, Snyder EL, Solheim BG, Stowell RG, Strauss RG, Petrides M, editors. Rossi’s Principles of Transfusion Medicine. 4th ed. Bethesda: AABB; 2009. pp. 811-825\n'},{id:"B2",body:'\nFlegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion. 2015;55:S47-S58. DOI: 10.1111/trf.13147\n'},{id:"B3",body:'\nPineda AA, Brzica SM Jr, Taswell HF. Hemolytic transfusion reactions: Recent experience in a large blood bank. Mayo Clinic Proceedings. 1978;53:378\n'},{id:"B4",body:'\nLichtiger B, Perry-Thorton E. Haemolytic transfusion reactions in oncology patients: Experience in a large cancer center. Journal of Clinical Oncology. 1984;25:438\n'},{id:"B5",body:'\nRobillard P, Itay KN, Chapdelaine A. Five-year trends in the incidence of serious adverse transfusion reactions in the Quebec Hemovigilance system (abstract). Transfusion. 2006;46(Suppl):86A\n'},{id:"B6",body:'\nAnnual SHOT Report 2017. Manchester, UK; 2018\n'},{id:"B7",body:'\nVamvalcas EC, Pineda AA, Reisner R, et al. The differentiation of delayed hemolytic and delayed hemolytic and delayed serologic transfusion reactions: Incidence and predictors of hemolysis. Transfusion. 1995;35:26-32\n'},{id:"B8",body:'\nAmbruso DR. Acute hemolytic transfusion reactions. In: Hillyer CD, Silberstein LE, Ness PM, Anderson KC, editors. Blood Banking and Transfusion Medicine—Basic Principles and Practice. Philadelphia: Churchill Livingstone; 2003. pp. 391-394\n'},{id:"B9",body:'\nNess PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: Incidence, long-term serologic findings and clinical significance. Transfusion. 1990;30:688-693\n'},{id:"B10",body:'\nRoback JD, Corubs MR, Grossman BJ, Hillyer CHD. Technical Manual. XVI ed. Bathesda: AABB; 2008. pp. 715-750\n'},{id:"B11",body:'\nDanfi L, Rondell P. Universality of anti-A and anti-B human isolysins. Vox Sanguinis. 1971;21:81-85\n'},{id:"B12",body:'\nMollison PL, Engelfriet CP, Contreras PM. Blood Transfusion in Clinical Medicine. 9th ed. Oxford Blackwell Scientific Publication; 1993. p. 487\n'},{id:"B13",body:'\nStrobel E. Hemolytic transfusion reactions. Transfusion Medicine and Hemotherapy. 2008;36:346-353\n'},{id:"B14",body:'\nDavenport RD. Management of transfusion reactions. In: Mintz PD, editor. Transfusion Therapy Clinical Principles and Practice. III ed. Bethesda: AABB; 2011. pp. 757-784\n'},{id:"B15",body:'\nBrodsky RA. Complement in haemolytic anaemia. Blood. 2015;126:2459-2465\n'},{id:"B16",body:'\nKumpel BM. Efficacy of RhD monoclonal antibodies in clinical trias as replacement therapy for prophylactic anti-D immunoglobulin: More questions than answers. Vox Sanguinis. 2007;93:99-111\n'},{id:"B17",body:'\nTelen MJ, Green AM. The Inab phenotype: Characterization of the membrane protein and complement regulatory defect. Blood. 1989;74:437-441\n'},{id:"B18",body:'\nPandey P, Anani WQ , Grotschal JL, Donomme GA. Potential impact of complement regulator deficiencies on haemolytic reactions due to minor ABO-mismatched transfusions. Blood Advances. 2017;1:1977-1982\n'},{id:"B19",body:'\nFrazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Advances in Clinical Chemistry. 2016;77:1-75\n'},{id:"B20",body:'\nUdani M, Rao N, Telen MJ. Leukocyte phenotypic changes in an in vitro model of ABO hemolytic transfusion reaction. Transfusion. 1997;37:904-909\n'},{id:"B21",body:'\nShirey RS, King KE, Ness PM. Hemolytic transfusion reactions: Acute and delayed. In: Hillyer CD, Silbestein LE, Ness PM, Anderson KC, Roback JD, editors. Blood Banking and Transfusion Medicine. Philadelphia: Elsevier; 2007. pp. 668-676\n'},{id:"B22",body:'\nDavenport RD, Strieter MM, Kunkel SL. Red cell ABO incompatibility and production of tumour necrosis factor-alpha. British Journal of Haematology. 1991;78:540-544\n'},{id:"B23",body:'\nDavenport RD, Strieter MM, Standiford TJ, Kunkel SL. Interleukin-8 production in red blood cell incompatibility. Blood. 1990;76:2439-2442\n'},{id:"B24",body:'\nEsmon CT. The impact of the inflammatory response on coagulation. Thrombosis Research. 2004;114:321-327\n'},{id:"B25",body:'\nDavenport RD, Burdick MD, Strieter RM, Kunkel SL. In vitro interleukin-1 receptor antagonist in IgG mediated red cell incompatibility. Transfusion. 1994;34:297-303\n'},{id:"B26",body:'\nLevi M, ten Cate H. Disseminated intravascular coagulation. The New England Journal of Medicine. 1999;341:586-592\n'},{id:"B27",body:'\nvan der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Seminars in Thrombosis and Hemostasis. 2001;27:639-651\n'},{id:"B28",body:'\nde Jonge E, Friederich PW, Levi M, van der Poll T. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin-6 and interlukin-8 release in healthy human subjects. Clinical and Diagnostic Laboratory Immunology. 2003;10:495-497\n'},{id:"B29",body:'\nTaylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thrombosis and Haemostasis. 2001;86:1327-1330\n'},{id:"B30",body:'\nToh CH, Hoots WK, On behalf of the SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of scientific and standardization committee on disseminated intravascular coagulation of the international society on thrombosis and haemostasis: A 5-year overview. Journal of Thrombosis and Haemostasis. 2007;5:604-606\n'},{id:"B31",body:'\nToh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagulation & Fibrinolysis. 2005;16:69-74\n'},{id:"B32",body:'\nJoseph K, Kaplan AP, Frederick WA. Formation of bradykinin: A major contributor to the innate inflammatory response. Advances in Immunology. 2005;86:159-208\n'},{id:"B33",body:'\nChan WL, Tang NL, Yim CC, et al. New features of renal lesion induced by stroma free hemoglobin. Toxicologic Pathology. 2000;28:635-642\n'},{id:"B34",body:'\nPatel RP. Biochemical aspects of the reaction of haemoglobin and NO: Implications for Hb-based blood substitutes. Free Radical Biology & Medicine. 2000;28:1518-1525\n'},{id:"B35",body:'\nVaughn MW, Huang KT, Kuo L, Liao JC. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. The Journal of Biological Chemistry. 2000;275:2342-2348\n'},{id:"B36",body:'\nGould SA, Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World Journal of Surgery. 1996;20:1200-1207\n'},{id:"B37",body:'\nKindgen-Milles D, Klement W, Arndt JO. The nociceptive systems of skin, poravascular tissue and hand veins of humans and their sensitivity to bradykinin. Neuroscience Letters. 1994;181:39-42\n'},{id:"B38",body:'\nLinden JV. Errors in transfusion medicine. Scope of the problem. Archives of Pathology & Laboratory Medicine. 1999;123:563-565\n'},{id:"B39",body:'\nJanatpour KA, Kalmin ND, Jensen HM, Holland PV. Clinical outcomes of ABO-incopatible RBC transfusion. American Journal of Clinical Pathology. 2008;129:276-281\n'},{id:"B40",body:'\nArnold PA, Garraty G. A retrospective analysis of the allue of monocyte monolayer assay result for predicting the clinical significance of blood group alloantibodies. Transfusion. 2004;44:1273-1281\n'},{id:"B41",body:'\nZimring JC, Spitalnik SL. Alloimmunization to red cell antigens and management of alloimmunized patients. In: Mintz P, editor. Transfusion Therapy Clinical Principles and Practice. 3rd ed. Bethesda, MD: AABB Press; 2011. pp. 631-642\n'},{id:"B42",body:'\nUnni N, Peddingghous M, Tormey CA, Stack G. Record fragmentation due to transfusion at multiple health care facilities: A risk factor for delayed hemolytic transfusion reactions. Transfusion. 2014;54:98-103\n'},{id:"B43",body:'\nSchonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion. 2000;40:1127-1131\n'},{id:"B44",body:'\nKing KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: Simultaneous destruction of recipients, cells. Transfusion. 1997;37:376-381\n'},{id:"B45",body:'\nAhrens N, Pruss A, Kahne A, et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion. 2007;47:813-816\n'},{id:"B46",body:'\nTalano JA, Hilley CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;40:e661-e665\n'},{id:"B47",body:'\nLarson LG, Welsh VJ, Ladd DJ. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion. 2000;40:902-906\n'},{id:"B48",body:'\nJosephson CD, Castillejo MI, Grima K, et al. ABO-mismatched platelet transfusions: Strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfusion and Apheresis Science. 2010;42:83-88\n'},{id:"B49",body:'\nIkebe E, Matsuoka S, Tanaka A, et al. Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study. Transfusion and Apheresis Science. 2019;58:162-168\n'},{id:"B50",body:'\nJosephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have “high-titer” anti A/AB: Implications for transfusion policy. Transfusion. 2004;44:805-808\n'},{id:"B51",body:'\nCooloing LW, Butch S, Downs T, Davenport R. Isoagglutinin titers in pooled group O platelets are comparable to apheresis platelets (abstract). Transfusion. 2007;47(Suppl):78A\n'},{id:"B52",body:'\nSadani DT, Urbanaiak SJ, Bruce M, Tighe JE. Repeat ABO-incompatible platelet transfusions leading to hamolytic transfusion reaction. Transfusion Medicine. 2006;16:375-379\n'},{id:"B53",body:'\nCooling L. ABO and platelet transfusion therapy. Immunohematology. 2007;23:2033\n'},{id:"B54",body:'\nCherin P, Marrie J, Michallet M, Pelus E, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Autoimmunity. 2016;15:71-81\n'},{id:"B55",body:'\nSpath PJ, Granata G, La Marra F, Knijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: The adverse events. Frontiers in Immunology. 2015;6:11\n'},{id:"B56",body:'\nPetz LD, Garatty G. Immune Hemolytic Anemia. 2nd ed. Philadelphia: Churchill Livingstone; 2004\n'},{id:"B57",body:'\nMota M, Bley C, Aravectia MG, et al. Autoantibody formation after alloimmunization inducing bystander immune hemolysis. Immunohematology. 2009;25:9-12\n'},{id:"B58",body:'\nPetz LD. The axpanding boundaries of transfusion medicine. In: Nance LTS, editor. Clinical Basic Science Aspects of Immunohematology. AABB: Arlington; 1991. pp. 73-113\n'},{id:"B59",body:'\nGarraty G. Severe reactions associated with transfusion of patients with sickle disease (editorial). Transfusion. 1997;37:357-361\n'},{id:"B60",body:'\nAlvarez A, Rivers S, Montoto S, et al. Relative sensitivity of direct antiglobulin test, antibody elution and flow cytometry in the serologic diagnosis of immune hemolytic transfusion reactions. Haematologica. 2000;85:181-188\n'},{id:"B61",body:'\nDzik W, Murphy A, Andreu G, et al. An international study of performance of sample collection from patients. Vox Sanguinis. 2003;85:40-47\n'},{id:"B62",body:'\nDavenport RD. Haemolytic transfusion reactions. In: Popovsky MA, editor. Transfusion Reactions. 3rd ed. Bethesda, MD: AABB Press; 2007. pp. 1-55\n'},{id:"B63",body:'\nWin N, Yeghen T, Needs M, et al. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Haematology. 2004;9:433-441\n'}],footnotes:[],contributors:[{corresp:"yes",contributorFullName:"Jolanta Korsak",address:"jkorsak@wim.mil.pl",affiliation:'
'}],corrections:null},book:{id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,fullTitle:"Human Blood Group Systems and Haemoglobinopathies",slug:"human-blood-group-systems-and-haemoglobinopathies",publishedDate:"February 17th 2021",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},profile:{item:{id:"109230",title:"Dr.",name:"Jorge",middleName:null,surname:"Rodriguez",email:"jorge.arce@live.com.mx",fullName:"Jorge Rodriguez",slug:"jorge-rodriguez",position:null,biography:null,institutionString:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",totalCites:0,totalChapterViews:"0",outsideEditionCount:0,totalAuthoredChapters:"1",totalEditedBooks:"0",personalWebsiteURL:null,twitterURL:null,linkedinURL:null,institution:{name:"Centro de Estudios e Investigaciones Técnicas de Gipuzkoa",institutionURL:null,country:{name:"Spain"}}},booksEdited:[],chaptersAuthored:[{title:"Training of Procedural Tasks Through the Use of Virtual Reality and Direct Aids",slug:"training-of-procedural-tasks-through-the-use-of-virtual-reality-and-direct-aids",abstract:null,signatures:"Jorge Rodríguez, Teresa Gutiérrez, Emilio J. Sánchez, Sara Casado and Iker Aguinaga",authors:[{id:"109230",title:"Dr.",name:"Jorge",surname:"Rodriguez",fullName:"Jorge Rodriguez",slug:"jorge-rodriguez",email:"jorge.arce@live.com.mx"},{id:"109833",title:"Dr.",name:"Emilio",surname:"Sánchez",fullName:"Emilio Sánchez",slug:"emilio-sanchez",email:"esanchez@ceit.es"},{id:"109998",title:"MSc.",name:"Teresa",surname:"Gutierrez",fullName:"Teresa Gutierrez",slug:"teresa-gutierrez",email:"teresa.gutierrez@tecnalia.com"},{id:"110000",title:"MSc.",name:"Sara",surname:"Casado",fullName:"Sara Casado",slug:"sara-casado",email:"sara.casado@tecnalia.com"},{id:"142378",title:"Dr.",name:"Iker",surname:"Aguinaga",fullName:"Iker Aguinaga",slug:"iker-aguinaga",email:"iaguinaga@ceit.es"}],book:{title:"Virtual Reality and Environments",slug:"virtual-reality-and-environments",productType:{id:"1",title:"Edited Volume"}}}],collaborators:[{id:"21147",title:"Dr.",name:"Moses",surname:"Onyesolu",slug:"moses-onyesolu",fullName:"Moses Onyesolu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/21147/images/4388_n.jpg",biography:"Moses Okechukwu Onyesolu has a Ph.D, M.Sc., and B.Sc. (Computer Science) from Nnamdi Azikiwe University, Nigeria where he works as a lecturer and researcher. His research interests are mainly in computer modeling and simulation, e-learning/virtual reality technologies, queueing system/theory and its applications. He has published widely in those areas. He is a member of the following learned societies: Nigerian Computer Society (NCS), Computer Professionals (Registration Council of Nigeria) (CPN), and International Association of Engineers (IAENG), International Association of Computer Science and Information Technology (IACSIT) and European Association for Programming Languages and Systems (EAPLS)",institutionString:null,institution:{name:"Nnamdi Azikiwe University",institutionURL:null,country:{name:"Nigeria"}}},{id:"107464",title:"Dr.",name:"Adriana",surname:"Peña Perez Negron",slug:"adriana-pena-perez-negron",fullName:"Adriana Peña Perez Negron",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Guadalajara",institutionURL:null,country:{name:"Mexico"}}},{id:"109833",title:"Dr.",name:"Emilio",surname:"Sánchez",slug:"emilio-sanchez",fullName:"Emilio Sánchez",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Centro de Estudios e Investigaciones Técnicas de Gipuzkoa",institutionURL:null,country:{name:"Spain"}}},{id:"109998",title:"MSc.",name:"Teresa",surname:"Gutierrez",slug:"teresa-gutierrez",fullName:"Teresa Gutierrez",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Tecnalia",institutionURL:null,country:{name:"Spain"}}},{id:"110000",title:"MSc.",name:"Sara",surname:"Casado",slug:"sara-casado",fullName:"Sara Casado",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Tecnalia",institutionURL:null,country:{name:"Spain"}}},{id:"111420",title:"Dr.",name:"Felix",surname:"Akinladejo",slug:"felix-akinladejo",fullName:"Felix Akinladejo",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology, Jamaica",institutionURL:null,country:{name:"Jamaica"}}},{id:"112789",title:"Dr.",name:"Raúl A.",surname:"Aguilar Vera",slug:"raul-a.-aguilar-vera",fullName:"Raúl A. Aguilar Vera",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Autonomous University of Yucatán",institutionURL:null,country:{name:"Mexico"}}},{id:"137834",title:"Mr.",name:"Ignatius",surname:"Ezeani",slug:"ignatius-ezeani",fullName:"Ignatius Ezeani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"137836",title:"Dr.",name:"Obikwelu Raphael",surname:"Okonkwo",slug:"obikwelu-raphael-okonkwo",fullName:"Obikwelu Raphael Okonkwo",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"142378",title:"Dr.",name:"Iker",surname:"Aguinaga",slug:"iker-aguinaga",fullName:"Iker Aguinaga",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null}]},generic:{page:{slug:"careers-at-intechopen",title:"Careers at IntechOpen",intro:"
Our business values are based on those any scientist applies to their research. The values of our business are based on the same ones that all good scientists apply to their research. We have created a culture of respect and collaboration within a relaxed, friendly, and progressive atmosphere, while maintaining academic rigour.
",metaTitle:"Careers at IntechOpen",metaDescription:"Employee quote to be added",metaKeywords:null,canonicalURL:"/page/careers-at-intechopen",contentRaw:'[{"type":"htmlEditorComponent","content":"
Integrity - We are consistent and dependable, always striving for precision and accuracy in the true spirit of science.
\\n\\n
Openness - We communicate honestly and transparently. We are open to constructive criticism and committed to learning from it.
\\n\\n
Disruptiveness - We are eager for discovery, for new ideas and for progression. We approach our work with creativity and determination, with a clear vision that drives us forward. We look beyond today and strive for a better tomorrow.
\\n\\n
What makes IntechOpen a great place to work?
\\n\\n
IntechOpen is a dynamic, vibrant company, where exceptional people are achieving great things. We offer a creative, dedicated, committed, and passionate environment but never lose sight of the fact that science and discovery is exciting and rewarding. We constantly strive to ensure that members of our community can work, travel, meet world-renowned researchers and grow their own career and develop their own experiences.
\\n\\n
If this sounds like a place that you would like to work, whether you are at the beginning of your career or are an experienced professional, we invite you to drop us a line and tell us why you could be the right person for IntechOpen.
Integrity - We are consistent and dependable, always striving for precision and accuracy in the true spirit of science.
\n\n
Openness - We communicate honestly and transparently. We are open to constructive criticism and committed to learning from it.
\n\n
Disruptiveness - We are eager for discovery, for new ideas and for progression. We approach our work with creativity and determination, with a clear vision that drives us forward. We look beyond today and strive for a better tomorrow.
\n\n
What makes IntechOpen a great place to work?
\n\n
IntechOpen is a dynamic, vibrant company, where exceptional people are achieving great things. We offer a creative, dedicated, committed, and passionate environment but never lose sight of the fact that science and discovery is exciting and rewarding. We constantly strive to ensure that members of our community can work, travel, meet world-renowned researchers and grow their own career and develop their own experiences.
\n\n
If this sounds like a place that you would like to work, whether you are at the beginning of your career or are an experienced professional, we invite you to drop us a line and tell us why you could be the right person for IntechOpen.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5240},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15812}],offset:12,limit:12,total:118381},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"12"},books:[{type:"book",id:"10760",title:"Steppe Biome",subtitle:null,isOpenForSubmission:!0,hash:"982f06cee6ee2f27339f3c263b3e6560",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10760.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10763",title:"Biodiversity of Ecosystems",subtitle:null,isOpenForSubmission:!0,hash:"c96b42d4539957c58dfc2eb8fd9ffc21",slug:null,bookSignature:"Dr. Levente Hufnagel",coverURL:"https://cdn.intechopen.com/books/images_new/10763.jpg",editedByType:null,editors:[{id:"10864",title:"Dr.",name:"Levente",surname:"Hufnagel",slug:"levente-hufnagel",fullName:"Levente Hufnagel"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10765",title:"Environmental Management",subtitle:null,isOpenForSubmission:!0,hash:"e5ba02fedd7c87f0ab66414f3b07de0c",slug:null,bookSignature:"Dr. John P. Tiefenbacher",coverURL:"https://cdn.intechopen.com/books/images_new/10765.jpg",editedByType:null,editors:[{id:"73876",title:"Dr.",name:"John P.",surname:"Tiefenbacher",slug:"john-p.-tiefenbacher",fullName:"John P. Tiefenbacher"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10766",title:"Landscape Architecture",subtitle:null,isOpenForSubmission:!0,hash:"a0a54a9ab661e4765fee76ce580cd121",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10766.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10845",title:"Marine Ecosystems",subtitle:null,isOpenForSubmission:!0,hash:"b369ac809068d2ebf1f8c26418cc6bec",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10845.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10846",title:"Stormwater",subtitle:null,isOpenForSubmission:!0,hash:"9bfae8caba192ce3ab6744c9cbefa210",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10846.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:19},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:21},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:6},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:6},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5252},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"16",title:"Medicine",slug:"medicine",parent:{title:"Health Sciences",slug:"health-sciences"},numberOfBooks:1511,numberOfAuthorsAndEditors:39573,numberOfWosCitations:21767,numberOfCrossrefCitations:11544,numberOfDimensionsCitations:29307,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"medicine",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editedByType:"Edited by",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9406",title:"Clinical Implementation of Bone Regeneration and Maintenance",subtitle:null,isOpenForSubmission:!1,hash:"875a140c01518fa7a9bceebd688b0147",slug:"clinical-implementation-of-bone-regeneration-and-maintenance",bookSignature:"Mike Barbeck, Nahum Rosenberg, Patrick Rider, Željka Perić Kačarević and Ole Jung",coverURL:"https://cdn.intechopen.com/books/images_new/9406.jpg",editedByType:"Edited by",editors:[{id:"204918",title:"Dr.",name:"Mike",middleName:null,surname:"Barbeck",slug:"mike-barbeck",fullName:"Mike Barbeck"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9122",title:"Cosmetic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"207026ca4a4125e17038e770d00ee152",slug:"cosmetic-surgery",bookSignature:"Yueh-Bih Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9122.jpg",editedByType:"Edited by",editors:[{id:"202122",title:"Prof.",name:"Yueh-Bih",middleName:null,surname:"Tang",slug:"yueh-bih-tang",fullName:"Yueh-Bih Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9134",title:"Recent Advances in Digital System Diagnosis and Management of Healthcare",subtitle:null,isOpenForSubmission:!1,hash:"ff00a5718f23cb880b7337b1c36b5434",slug:"recent-advances-in-digital-system-diagnosis-and-management-of-healthcare",bookSignature:"Kamran Sartipi and Thierry Edoh",coverURL:"https://cdn.intechopen.com/books/images_new/9134.jpg",editedByType:"Edited by",editors:[{id:"29601",title:"Dr.",name:"Kamran",middleName:null,surname:"Sartipi",slug:"kamran-sartipi",fullName:"Kamran Sartipi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editedByType:"Edited by",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editedByType:"Edited by",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editedByType:"Edited by",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9018",title:"Some RNA Viruses",subtitle:null,isOpenForSubmission:!1,hash:"a5cae846dbe3692495fc4add2f60fd84",slug:"some-rna-viruses",bookSignature:"Yogendra Shah and Eltayb Abuelzein",coverURL:"https://cdn.intechopen.com/books/images_new/9018.jpg",editedByType:"Edited by",editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",middleName:null,surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9523",title:"Oral and Maxillofacial Surgery",subtitle:null,isOpenForSubmission:!1,hash:"5eb6ec2db961a6c8965d11180a58d5c1",slug:"oral-and-maxillofacial-surgery",bookSignature:"Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/9523.jpg",editedByType:"Edited by",editors:[{id:"82453",title:"Dr.",name:"Gokul",middleName:null,surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:1511,mostCitedChapters:[{id:"19013",doi:"10.5772/21983",title:"Cell Responses to Surface and Architecture of Tissue Engineering Scaffolds",slug:"cell-responses-to-surface-and-architecture-of-tissue-engineering-scaffolds",totalDownloads:9697,totalCrossrefCites:109,totalDimensionsCites:230,book:{slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",title:"Regenerative Medicine and Tissue Engineering",fullTitle:"Regenerative Medicine and Tissue Engineering - Cells and Biomaterials"},signatures:"Hsin-I Chang and Yiwei Wang",authors:[{id:"45747",title:"Dr.",name:"Hsin-I",middleName:null,surname:"Chang",slug:"hsin-i-chang",fullName:"Hsin-I Chang"},{id:"53659",title:"Ms.",name:"Yiwei",middleName:null,surname:"Wang",slug:"yiwei-wang",fullName:"Yiwei Wang"}]},{id:"46479",doi:"10.5772/57353",title:"Floating Drug Delivery Systems for Eradication of Helicobacter pylori in Treatment of Peptic Ulcer Disease",slug:"floating-drug-delivery-systems-for-eradication-of-helicobacter-pylori-in-treatment-of-peptic-ulcer-d",totalDownloads:1995,totalCrossrefCites:79,totalDimensionsCites:180,book:{slug:"trends-in-helicobacter-pylori-infection",title:"Trends in Helicobacter pylori Infection",fullTitle:"Trends in Helicobacter pylori Infection"},signatures:"Yousef Javadzadeh and Sanaz Hamedeyazdan",authors:[{id:"94276",title:"Prof.",name:"Yousef",middleName:null,surname:"Javadzadeh",slug:"yousef-javadzadeh",fullName:"Yousef Javadzadeh"},{id:"98229",title:"Dr.",name:"Sanaz",middleName:null,surname:"Hamedeyazdan",slug:"sanaz-hamedeyazdan",fullName:"Sanaz Hamedeyazdan"}]},{id:"25512",doi:"10.5772/30872",title:"Epidemiology of Psychological Distress",slug:"epidemiology-of-psychological-distress",totalDownloads:8066,totalCrossrefCites:57,totalDimensionsCites:145,book:{slug:"mental-illnesses-understanding-prediction-and-control",title:"Mental Illnesses",fullTitle:"Mental Illnesses - Understanding, Prediction and Control"},signatures:"Aline Drapeau, Alain Marchand and Dominic Beaulieu-Prévost",authors:[{id:"84582",title:"Dr.",name:"Aline",middleName:null,surname:"Drapeau",slug:"aline-drapeau",fullName:"Aline Drapeau"},{id:"84605",title:"Dr.",name:"Alain",middleName:null,surname:"Marchand",slug:"alain-marchand",fullName:"Alain Marchand"},{id:"84606",title:"Dr.",name:"Dominic",middleName:null,surname:"Beaulieu-Prévost",slug:"dominic-beaulieu-prevost",fullName:"Dominic Beaulieu-Prévost"}]}],mostDownloadedChaptersLast30Days:[{id:"43758",title:"Anxiety Disorders in Pregnancy and the Postpartum Period",slug:"anxiety-disorders-in-pregnancy-and-the-postpartum-period",totalDownloads:39763,totalCrossrefCites:11,totalDimensionsCites:20,book:{slug:"new-insights-into-anxiety-disorders",title:"New Insights into Anxiety Disorders",fullTitle:"New Insights into Anxiety Disorders"},signatures:"Roberta Anniverno, Alessandra Bramante, Claudio Mencacci and Federico Durbano",authors:[{id:"157077",title:"Dr.",name:"Federico",middleName:null,surname:"Durbano",slug:"federico-durbano",fullName:"Federico Durbano"},{id:"166382",title:"Dr.",name:"Roberta",middleName:null,surname:"Anniverno",slug:"roberta-anniverno",fullName:"Roberta Anniverno"}]},{id:"70711",title:"Fetal Growth Restriction",slug:"fetal-growth-restriction",totalDownloads:1706,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"growth-disorders-and-acromegaly",title:"Growth Disorders and Acromegaly",fullTitle:"Growth Disorders and Acromegaly"},signatures:"Edurne Mazarico Gallego, Ariadna Torrecillas Pujol, Alex Joan Cahuana Bartra and Maria Dolores Gómez Roig",authors:[{id:"202446",title:"Ph.D.",name:"Maria Dolores",middleName:null,surname:"Gómez Roig",slug:"maria-dolores-gomez-roig",fullName:"Maria Dolores Gómez Roig"},{id:"311835",title:"Dr.",name:"Edurne",middleName:null,surname:"Mazarico",slug:"edurne-mazarico",fullName:"Edurne Mazarico"}]},{id:"70405",title:"Hemostasis in Cardiac Surgery: How We Do it with Limited Resources",slug:"hemostasis-in-cardiac-surgery-how-we-do-it-with-limited-resources",totalDownloads:2694,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:null,title:"Contemporary Applications of Biologic Hemostatic Agents across Surgical Specialties - Volume 1",fullTitle:"Contemporary Applications of Biologic Hemostatic Agents across Surgical Specialties - Volume 1"},signatures:"Fevzi Sarper Türker",authors:null},{id:"64851",title:"Herbal Medicines in African Traditional Medicine",slug:"herbal-medicines-in-african-traditional-medicine",totalDownloads:9954,totalCrossrefCites:10,totalDimensionsCites:17,book:{slug:"herbal-medicine",title:"Herbal Medicine",fullTitle:"Herbal Medicine"},signatures:"Ezekwesili-Ofili Josephine Ozioma and Okaka Antoinette Nwamaka\nChinwe",authors:[{id:"191264",title:"Prof.",name:"Josephine",middleName:"Ozioma",surname:"Ezekwesili-Ofili",slug:"josephine-ezekwesili-ofili",fullName:"Josephine Ezekwesili-Ofili"},{id:"211585",title:"Prof.",name:"Antoinette",middleName:null,surname:"Okaka",slug:"antoinette-okaka",fullName:"Antoinette Okaka"}]},{id:"59779",title:"Effective Communication in Nursing",slug:"effective-communication-in-nursing",totalDownloads:6504,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"nursing",title:"Nursing",fullTitle:"Nursing"},signatures:"Maureen Nokuthula Sibiya",authors:[{id:"73330",title:"Dr.",name:"Nokuthula",middleName:null,surname:"Sibiya",slug:"nokuthula-sibiya",fullName:"Nokuthula Sibiya"}]},{id:"64858",title:"The Neurobiology of Anorexia Nervosa",slug:"the-neurobiology-of-anorexia-nervosa",totalDownloads:892,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"anorexia-and-bulimia-nervosa",title:"Anorexia and Bulimia Nervosa",fullTitle:"Anorexia and Bulimia Nervosa"},signatures:"Ashley Higgins",authors:null},{id:"63771",title:"The Role of Catheter Reshaping at the Angiographic Success",slug:"the-role-of-catheter-reshaping-at-the-angiographic-success",totalDownloads:536,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"angiography",title:"Angiography",fullTitle:"Angiography"},signatures:"Yakup Balaban",authors:[{id:"252647",title:"Associate Prof.",name:"Yakup",middleName:null,surname:"Balaban",slug:"yakup-balaban",fullName:"Yakup Balaban"}]},{id:"61866",title:"Plants Secondary Metabolites: The Key Drivers of the Pharmacological Actions of Medicinal Plants",slug:"plants-secondary-metabolites-the-key-drivers-of-the-pharmacological-actions-of-medicinal-plants",totalDownloads:5564,totalCrossrefCites:13,totalDimensionsCites:32,book:{slug:"herbal-medicine",title:"Herbal Medicine",fullTitle:"Herbal Medicine"},signatures:"Rehab A. Hussein and Amira A. El-Anssary",authors:[{id:"212117",title:"Dr.",name:"Rehab",middleName:null,surname:"Hussein",slug:"rehab-hussein",fullName:"Rehab Hussein"},{id:"221140",title:"Dr.",name:"Amira",middleName:null,surname:"El-Anssary",slug:"amira-el-anssary",fullName:"Amira El-Anssary"}]},{id:"17956",title:"Sexual and Reproductive Function in Chronic Kidney Disease and Effect of Kidney Transplantation",slug:"sexual-and-reproductive-function-in-chronic-kidney-disease-and-effect-of-kidney-transplantation",totalDownloads:11790,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"after-the-kidney-transplant-the-patients-and-their-allograft",title:"After the Kidney Transplant",fullTitle:"After the Kidney Transplant - The Patients and Their Allograft"},signatures:"Mahboob Lessan-Pezeshki and Shirin Ghazizadeh",authors:[{id:"26564",title:"Prof.",name:"Mahboob",middleName:null,surname:"Lessan Pezeshki",slug:"mahboob-lessan-pezeshki",fullName:"Mahboob Lessan Pezeshki"},{id:"26571",title:"Prof.",name:"Shirin",middleName:null,surname:"Ghazizadeh",slug:"shirin-ghazizadeh",fullName:"Shirin Ghazizadeh"}]},{id:"64747",title:"Bone Development and Growth",slug:"bone-development-and-growth",totalDownloads:3711,totalCrossrefCites:6,totalDimensionsCites:9,book:{slug:"osteogenesis-and-bone-regeneration",title:"Osteogenesis and Bone Regeneration",fullTitle:"Osteogenesis and Bone Regeneration"},signatures:"Rosy Setiawati and Paulus Rahardjo",authors:null}],onlineFirstChaptersFilter:{topicSlug:"medicine",limit:3,offset:0},onlineFirstChaptersCollection:[{id:"75604",title:"Normal Puerperium",slug:"normal-puerperium",totalDownloads:0,totalDimensionsCites:null,doi:"10.5772/intechopen.96348",book:{title:"Midwifery"},signatures:"Subrat Panda, Ananya Das, Arindam Mallik and Surajit Ray Baruah"},{id:"75596",title:"The Use of a Dynamic Elastomeric Fabric Orthotic Intervention in Adolescents and Adults with Scoliosis",slug:"the-use-of-a-dynamic-elastomeric-fabric-orthotic-intervention-in-adolescents-and-adults-with-scolios",totalDownloads:0,totalDimensionsCites:null,doi:"10.5772/intechopen.96391",book:{title:"Spinal Deformities in Adolescents, Adults and Older Adults"},signatures:"Martin Matthews and James Wynne"},{id:"75582",title:"Elimination of Plasmodium vivax Malaria: Problems and Solutions",slug:"elimination-of-plasmodium-vivax-malaria-problems-and-solutions",totalDownloads:1,totalDimensionsCites:null,doi:"10.5772/intechopen.96604",book:{title:"Current Topics and Emerging Issues in Malaria Elimination"},signatures:"Liwang Cui, Awtum Brashear, Lynette Menezes and John Adams"}],onlineFirstChaptersTotal:652},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/109230/jorge-rodriguez",hash:"",query:{},params:{id:"109230",slug:"jorge-rodriguez"},fullPath:"/profiles/109230/jorge-rodriguez",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()